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1. Endocannabinoid system (ECS) 
 
The discovery of the major psychoactive principle in Cannabis Sativa, Δ9-
tetrahydrocannabinol (Δ9–THC), leads in the mid-1990s to the characterization of a 
neuromodulatory network called Endocannabinoid system (ECS). This term now 
indicates a whole signalling system that comprises cannabinoid receptors, endogenous 
ligands and enzymes for ligand biosynthesis, inactivation and transport
1
.  
The endocannabinoid signaling system is formed of  two G-protein-coupled-
cannabinoid receptors (CBRs), that are activated by small lipid mediators, known as 
endocannabinoids (eCBs), and by Cannabis-derived drugs, together with the associated 
biochemical machinery (precursors, synthesis and degradative enzymes, and 
transporters). Preparation of cannabis extract have been used as recreational purposes 
but also as medicinal agent because CBRs-related processes are involved in cognition, 
memory, anxiety, control of appetite, emesis, motor behaviour, sensory, autonomic and 
neuroendocrin responses; Endocannabinoids also induce hypotension and bradycardia, 
inhibit cell growth, affect energy metabolism, modulate immune responses and have 
widely accepted anti-inﬂammatory effects 2. The cloning of the cannabinoid receptors 
allows the identification of their endogenous ligands; the endocannabinoids where 
found to be derivatives of arachidonic acid conjugated with a polar head group, 
ethanolamine or glycerol, by amide, such as anandamide or N-
arachidonoylethanolamine, (AEA) N-arachidonoyl-dopamine (NADA), ester 
arachidonoylglycerol or 2‐AG and virodhamine, or ether moieties (2‐arachidylglycerol 
or noladin ether) (Fig.1). The first endocannabinoid to be discovered was anandamide, 
then 2-AG also exhibits high affinity for CB1 and CB2 receptors. Among these lipid 
mediators, anandamide and 2-arachidonoylglycerol acid have a relevant role for their 
pharmacology and metabolism 
3,4
 . 
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Fig. 1 Structures of the cannabinoid receptor ligands 3. 
 
1.1 Endocannabinoid receptors 
Cannabinoid receptors (CBRs) are a class of cell membrane metabotropic receptors 
belonging to the superfamily of G-protein-coupled receptors (GPCRs). Nowadays, there 
are two well-known subtypes of cannabinoid receptors CB1 (CB1R) and CB2 (CB2R).  
After the screening of various orphan G-protein-coupled receptors that show some 
affinities with THC, the first THC-specific receptor, the cannabinoid receptor type-1 
(CB1), has been identified and then cloned. The second cannabinoid receptor, named 
CB2, was identified  with homology cloning 
3
. CB1 and CB2 receptors belonging to the 
superfamily of receptors that couple to guanine-nucleotide binding-proteins (G-protein) 
and possess seven hydrophobic transmembrane segments connected by alternating 
extracellular and intracellular loops and two domains: an N-terminal extracellular 
domain with glycosylation sites and a C-terminal intracellular domain coupled to a G-
protein complex. The distinction between these receptors is based on differences in their 
amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to 
several potent agonists and antagonists that show marked selectivity for one or the other 
Endocannabinoid system 
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receptor type. Cannabinoid receptors CB1 and CB2 share 48% amino acid sequence
 7
.  
 
 
             Fig. 2  Structures of CB1 and CB2 receptors 
5. 
 
CB1 receptors are highly expressed in the hippocampus, some olfactory regions, 
caudate, putamen, accumbens nucleus (ventral striatum), the substantia nigra pars 
reticulata (SNr), globus pallidus, and the horizontal limb of the diagonal band. The 
disruptive effects of THC and related compounds on memory and cognition is closely 
related to the high density of CB1 receptors in brain, especially in the hippocampus. The 
presence of CB1 receptors in the basal ganglia confirm the relationship between 
endocannabinoids and fine-tuning of motor control. Moreover, in neurodegenerative 
diseases, such as Parkinson's and Huntington's, CB1 receptor binding is decreased: this 
pathologies are neurological disorders of extrapyramidal system, in which the 
disturbance of CB1 receptors expression and binding seems to play an essential role for 
the development of the disorder. Thus, CB1 receptors are highly expressed in the areas 
which are involved in pain modulation, including the periaqueductal gray and the dorsal 
horn of the spinal cord. Despite their principal localization in the central system, CB1 
receptors are also distributed in the periphery even if in lower levels, including immune 
and reproductive systems, liver, intestine, vascular endothelium, and peripheral nerve 
Endocannabinoid system 
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synapses 
6,7
.  
CB2 receptors are primarily located in cells involved in immune and inflammatory 
responses.
 
 Even if initially thought to be only expressed in the periphery, CB2 receptors 
were found in the cerebellum, in the brainstem
 
 and in microglial cells, where may play 
a central role in modulation of their mobility and function both in vitro and in vivo
 10
. 
Moderate density of CB2 immunopositive cell bodies were found in the periaqueductal 
gray (PAG), substantia nigra pars reticulata, and other nuclear structures of the brain 
stem. CB2 receptor modulation has been implicated also in several processes such as 
analgesia, hepatic ﬁbrosis, bone growth, and atherosclerosis  6,7. 
 Besides CB1 and CB2 receptors, there are some evidences for additional CB‐like 
receptors (such as GPR55, GPR18, TRPVchannels, etc.) 
8,9
. 
 
1.2 Mechanism of endocannabinoid neuronal 
signaling 
The mechanisms of endocannabinoid signaling in the nervous system is different from 
those of the classic neurotransmission systems. In the classic model the depolarization 
of the pre-synaptic neuron is caused by an action potential and produces a signal that 
traverses the synaptic clef to bind and stimulate their kindred receptors on the 
postsynaptic neuron. Endocannabinoids are synthesized and secreted by postsynaptic 
neurons and traverse the synaptic cleft to stimulate CB1 receptors on presynaptic axon 
terminal; for this reason, they are hypothesized to act as retrograde messengers. This 
way is used by the neuronal system to convey information about the activity of neurons 
back to cells that innervate. Activation of CB1 receptors then modulates signaling within 
the presynapse, producing a transient or prolonged reduction in the release of 
neurotransmitters. This model is supported by a large number of in vitro 
electrophysiological studies 
10,11
. Activated CB1 receptors match principally through the 
Gi/Go class of G proteins to regulate calcium and potassium channels and reduce the 
probability of neurotransmitter release 
12
. This suppression can result in the inhibition 
or, paradoxically, disinhibition of neuronal circuits, if the CB1 receptor is expressed on 
Endocannabinoid system 
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glutamatergic or GABAergic neurons (Fig. 3) 
4
.  
The activation of CB1 or CB2 receptors typically blocks adenylate cyclase, preceding 
signaling through cyclic AMP, and regulating cAMP-dependent kinase A (PKA) protein 
functions.    
 
Fig. 3 General model for endocannabinoid-based retrograde signaling. Postsynaptic receptors like AMPA  and 
NMDA and voltage-gated ion channels are activated by releasing of neurotransmitter, allowing inﬂux of Ca2+ and 
on-demand endocannabinoid biosynthesis. Anandamide and 2-AG migrate from postsynaptic neurons to CB1 
receptors  located on presynaptic neurons. Once activated, CB1 receptors couple through the Gi/Go class of G-
proteins to regulate ion channels and inhibit neurotransmitter release. The retrograde signaling of endocannabinoids 
is then terminated by degradative enzymes: FAAH in the postsynaptic neuron, MAGL in the presynaptic neuron 4. 
 
For example, in the hippocampus, CB1 receptors are more abundant on inhibitory 
GABA terminals than on excitatory glutamate terminals. Stimulation of CB1 
receptors by 2-AG on presynaptic terminals strongly reduces the release of the 
inhibitory neurotransmitter GABA and less decreases the release of the stimulating 
Endocannabinoid system 
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glutamate. The synthesis of new 2-AG is limited by the partial inhibition of glutamate 
signaling, while old 2-AG is inactivated by MAGL. The reduction of anandamide as 
well as 2-AG can also be achieved by FAAH. The overproduction of endocannabinoids 
(or excessive intake) leads to a stronger inhibition of glutamate signaling, that could 
damage hippocampus-dependent learning and memory. Moreover, interaction with 
cannabinoid receptors activates other protein kinase, like p38 mitogen-activated protein 
kinase (MAPK), focal adhesion kinase (FAK), c-jun N-terminal kinase (JNK) and 
extracellular signal-regulated kinase (ERK). CB1 receptor activation also controls 
calcium or potassium conductance, properties indispensable to the suppression of 
neuronal excitability and neurotransmitter release 
4, 13
. 
 
1.3 Endocannabinoids biosynthesis 
The mechanisms of endocannabinoid signaling is very different from those of the 
classic neurotransmission systems (e.g., cholinergic, aminoacidergic, and 
monoaminergic). In the classic model of neurotransmission, an action potential comes 
to the presynaptic neuron and causes the release of neurotransmitters, that traverse 
thesynaptic cleft to bind and activate their receptors on the postsynaptic neuron. 
Endocanabinoids are not accumulated inside of synaptic vesicles, but are formed in cell 
membranes, stored as lipid precursors and released following activation of the enzymes 
catalyzing the hydrolysis of their precursors 
14
. Nowaday, anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) are the most characterized.  
Anandamide is a partial agonist at CB1 and CB2 receptors and mimics most of the 
pharmacological effects produced by cannabinoid drugs in vitro and in vivo. The 
mechanisms of anandamide biosynthesis in the nervous system are incompletely clear.  
There is now strongly evidence for phospholipid-derived, however diverging, pathways 
for the cerebral biosynthesis of anandamide and 2-AG 
15
.  It is generally approved that 
the mechanism which generates anandamide is based on a calcium-dependent 
enzymatic transfer of arachidonic acid from the sn-1 position of membrane 
phospholipids to the amine of phosphatidylethanolamine (PE) to form N-arachidonoyl 
phosphatidylethanolamine (NArPE), then it is hydrolyzed to give anandamide. 
Endocannabinoid system 
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Nevertheless, the convertion of NArPE into anandamide is not totally clear, because the 
calcium-dependent transacylase enzyme (CDTA) that forms NArPE has still not been 
molecularly identified (Fig.4). The second step is NArPE hydrolysis by a Ca2
+
-sensitive 
NAPE-selective phospholipase D (NAPE-PLD); thanks to its molecular cloning it is 
possible to adfirm that it is a phosphodiesterase of the metallo-betalactamase family, 
and the characterization of the purified enzyme confirmed that membrane components 
such as phosphatidylethanolamine maintain active NAPE-PDL in its membrane-
associated form. It is important that even though anandamide is produced on demand, 
NAPE-PLD seems to be kept in a constitutively active form 
14
.  
 
                                                          Fig. 4  Direct anandamide biosynthesis 17. 
 
Even if the transacylation–phosphodiesterase pathway is considered the major route for 
anandamide production, thanks to the generation of NAPE-PLD knockout mice it has 
been demonstrated the presence of other metabolic pathways for anandamide synthesis. 
These mice, in fact, have wild-type brain levels of anandamide, in contrast with the high 
decrease of long-chain saturated NAE levels. Therefore, two pathways distinct from 
NAPE-PLD are now being characterized (Fig. 5a). One pathway uses as key 
intermediates glycerophospho-N-acylethanolamine lipids (GP-NAEs). The serine 
hydrolase ABHD4 (α/β-hydrolase 4, Abh4) has been proposed as a B-type lipase 
producing GP-NAEs by double O-deacylation of NAPEs. In fact, cells that show an 
overexpression of ABHD4 has enhanced levels of both NAPE-lipase and lyso-NAPE-
Endocannabinoid system 
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lipase activities, with a marked preference by ABHD4 for lyso-NAPE substrates over 
other lysophospholipids. The characterization of glycerophosphodiesterase 1 (GDE1) as 
a metal-dependent GP-NAE phosphodiesterase confirm GP-NAEs’ role as intermediate 
in anandamide synthesis, togheter with their discovery in mouse brain. GDE1 is an 
integral membrane protein highly expressed in central nervous system and showing 
highest activity with C16:0, C18:1 and C20:4 substrates, that are typically the substrates 
less affected by NAPE-PLD invalidation in mouse brain.  
Another pathway, that uses phospho-N-arachidonoylethanolamine (pAEA) as a key 
intermediate in the synthesis of anandamide, has been mainly characterized in 
macrophagelike RAW264.7 cells. These cells have increased anandamide levels but 
decreased NAPE-PLD expression in presence of lipopolysaccharide (LPS). In the same 
conditions, expression of the phosphatase protein tyrosine phosphatase PTPN22 is 
enhanced and pAEA detected. The confirm of the role of PTPN22 in LPS-induced 
increasing of anandamide levels comes from experiments in LPS-activated RAW264.7 
cells, in which the silencing of PTPN22 leads to a decreasing of anandamide levels. 
Thus, this pathway involves a PLC that produces pAEA from N-
arachidonoylphosphatidylethanolamine; pAEA, in turn, is hydrolyzed into anandamide 
by a phosphatase, with PTPN22 and SHIP1 as first candidates for this activity. 
Compared with wild-types animals, PTPN22 and SHIP1 knockout mices present an 
high reduction of the conversion of pAEA to anandamide; however, only a small 
reduction in anandamide levels was observed in PTPN-/-mice brain. It is possible that 
with stimulation (for example under inflammatory conditions), anandamide levels 
would further differ between PTPN-/- and wild-type animals. Significantly, only data 
relevant to anandamide synthesis  have been reported, shown a more selective affinity 
for anandamide than the other NAEs 
16
. 
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Fig.5a Anandamide biosynthetic pathways 16 
 
 
2-arachidonoylglycerol is produced in a stimulus-dependent way in both nervous 
system and peripheral cells. Stimuli can be cell depolarization, inducing a strong 
Ca2
+
 influx, activation of Gq/11-coupled-receptors, such as metabotropic 
glutamate receptors, or a combination of both mechanisms bringing to increased 
2-arachidonoylglycerol production. 2-AG can be synthesized in two steps with the 
generation of 1-acyl-2-arachidonoylglycerol (DAG) from phosphatidylinositol 
thanks to PLC activity and following hydrolysis of DAG by a diacylglycerol 
lipase (Fig.5b). It seems that the 2-arachidonoylglycerol retrograde signaling after 
activation of Gq/ 11-type-coupled-receptors depends on this PLCb-DAGL 
pathway. In fact, this signaling is absent in brain preparations from PLCb 
knockout mice or after inhibition of these enzymes. The molecular cloning of sn1-
DAGLa and sn1-DAGLb was important in characterizing 2-arachidonoylglycerol 
Endocannabinoid system 
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biosynthesis. Cellular activity of these enzymes correlates with 2-
arachidonoylglycerol production and, contrarywise, their inhibition lead to a 
decreasing of endocannabinoid levels. An alternative pathway to PLC-driven 
DAG production is the synthesis of DAG by a phosphatidic acid hydrolase from 
phosphatidic acid. 
A second pathway bringing to 2-AG involves a 2-arachidonoyl-
lysophosphatidylinositol (lyso-PI) intermediate. In this way there is the sequential 
actions of a phosphatidylinositol-preferring phospholipase A1, producing the lyso-
PI intermediate, and of a lysophosphatidylinositol-selective phospholipase C 
(lyso-PLC) producing 2-arachidonoylglycerol. However, the relevance of this 
pathway in generating 2-arachidonoylglycerol is less clear, compared with the 
PLC-DAGL pathway; in fact, most of these molecules, including DAG and 2-
arachidonoylglycerol, are intermediates in several pathways, the most important of 
which is arachidonic acid release. It is therefore probable that not all the pathways 
leading to 2-arachidonoylglycerol are actually involved in physiological 
cannabinoid signaling 
16
. 
 
 
 
Fig. 5b 2-Arachidonoylglycerol biosynthesis 16 
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1.4 Enzymes involved in endocannabinoids 
degradation 
Anandamide and 2-arachidonoylglycerol, after being released in the synaptic cleft and 
completing their biological actions, are degraded by a metabolizing system, consisting 
of two major serine hydrolase enzymes, fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL), and two recently discovered enzymes, ABDH6 and 
ABDH12. 
1.4.1 FAAH 
FAAH is a ~60 kDa integral membrane protein with a single N-terminal transmembrane 
domain, composed by a 579 amino acid sequence and able to metabolize several fatty 
acid amides. It contains a higly conserved region of 56 amino acids rich in serine, 
glycine and alanine residues that is highly homologous to the “amidase signature” found 
in a family of bacterial and fungal amidases. At the same time, it can be considered a 
serine hydrolase: in fact, the finding that PMSF (phenylmethylsulfonyl fluoride) is a 
potent inhibitor of FAAH activity implicates serine residues as crucial for catalytic 
action, since PMSF sulfonylates the hydroxyl groups of serine. Unlike most serine 
hydrolases, which use a histidine residue as a catalytic base, FAAH employs a lysine for 
the same function, peculiarity that enables FAAH to hydrolyze both amides and esters 
at equivalent rates. Structural determination of the transmembrane-truncated rat enzyme 
bound to the nonselective inhibitor methyl arachidonoylfluorophosphonate confirmed 
the presence of a serine-serine-lysine (Ser
241
-Ser
217
-Lys
142
) catalytic triad, typical for 
amidase signature enzymes and different from the serine-histidine-aspartatic acid, motif 
common to most serine hydrolases 
18
.   
FAAH is highly expressed in the mammalian brain where it is located in the 
intracellular membranes of postsynaptic soma and dendrites. FAAH is the main 
responsible of anandamide metabolism, through the process of hydrolysis is free 
ethanolamine and arachidonic acid. 
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 Fig. 6 Degradation of anandamide by FAAH 19. 
 
FAAH is distributed largely through the body, and is found in brain, liver, testes, uterus, 
kidney, ocular tissues, spleen, and possibly lung, but not in skeletal muscle or heart. 
Within the brain, FAAH expression varies from region to region, with the highest 
activities being found in the globus pallidus and hippocampus, and the lowest in the 
medulla. The sensitivity of FAAH to different inhibitors is similar in different brain 
regions. Expression of FAAH in large neurons and in non- neuronal epithelial cells in 
the choroid plexus has been reported. Across the brain and in the retina, FAAH has a 
cellular localization complementary (although with little or no actual co-localization) to 
the CB1 receptors. Therefore, other metabolic pathways are responsible for stopping 
anandamide signal. For example, COX-2 (the inducible form of COX) degradates 
anandamide; this is confirmed in neurodegenerative deseases or in tissues damages, in 
which FAAH activity is affect or COX-2 is upregulated. In fact, COX-2 metabolic 
pathway becomes physiologically relevant in FAAH -/- mice, where the administration 
of exogenous anandamide leads to the production of detectable levels of prostamide. In 
addition, lipoxygenases (12‐LOX and 15‐LOX) and cytochrome P450, including its 
major brain isoform CYP2D6, convert AEA into biologically active metabolites that 
exert their biological actions via cannabinoid, PPAR and TRPV1 receptors. However, 
the functional role of these substances in the CNS has not been determined 
17,18
.  
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Fig.7 Alternative ways of degradation of anandamide 20. 
 
 
1.4.2 MAGL 
The most important enzymatic route for 2-AG inactivation in brain is via hydrolysis 
generating AA and glycerol, thanks to the action of MAGL. MAGL was originally 
purified and cloned from the adipose tissue, accordingly with his function as a key 
lipolytic enzyme, but several studies demonstrated his central role in other processes 
like infiammation, pain, cancer, neurodegenerative deseases. However, the highest 
expression of MAGL is in brain, cerebellum, cortex, thalamus, and hippocampus where 
is localized in presynaptic terminals, like CB1 receptors, and where it has a key action in 
the degradation of 2-AG. 2-AG can also be metabolized by FAAH, even if it is most 
hydrolizes by MAGL in intact neurons, and similary to anandamide, it is a presumed 
substrate of COX and LOX enzymes 
21
.  
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Fig.8  Endocannabinoid hydrolysis. In the nervous system, in the liver and adipose  tissue  2-AG is 
degraded primarily by MAGL 51. 
At the beginning, important observations about brain 2-AG hydrolases were made 
thanks to the use of pharmacological inhibitors: Methylarachidonylﬂuorophosphonate 
(MAFP) is one of the most potent MAGL inhibitors discovered. MAFP inhibits MAGL 
irreversibly but it is not very selective, because it inhibits most members of the 
metabolic serine hydrolase family. Then, was developed N-arachidonoyl maleimide 
(NAM) as a cysteine targeting irreversible inhibitor of MAGL-like activity in rat 
cerebellar membranes. The major difference between the two compounds is the residual 
activity in 2-AG hydrolysis: MAFP totally blocks brain 2-AG hydrolysis, meanwhile 
about 15% residual activity remained after maximally effective concentration of NAM. 
Some studies evidenced that the NAM-resistant activity is caused by other two serine 
hydrolases, namely ABHD6 and ABHD12, because of its low selectivity. Recently, a 
new carbamate compound known as JZL184 was presented as a potent and speciﬁc 
MAGL inhibitor; the selectivity of JZL184 for MAGL over other brain serine 
hydrolases was demonstrated using ABPP, a powerful proteomic instrument allowing 
inhibitor activity proﬁling in complex proteomes. Indeed, recent studies utilizing these 
inhibitors both in vitro and in vivo have demonstrated the importance of MAGL as the 
major regulator of not only brain 2-AG levels but also various CB1 receptors-dependent 
Endocannabinoid system 
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cellular and behavioural responses 
21,22
. 
1.4.3 ABHD6 
ABHD6 is a post-genomic protein of 30 kDa, and little is known of its physiological 
functions, but several studies indicates that ABHD6 might serve as a new diagnostic 
marker of certain form of tumours, since high expression of ABHD6 has been reported 
in these tumours; however, its knockdown in cancer cells did not inhibit tumour cell 
growth.  
ABHD6 is an integral membrane protein with a  fully conserved catalytic triad 
(postulated amino acid residues Ser
246
-Asp
333
-Hys
372
), that possesses typical α/β-
hydrolase family ﬁngerprints such as the lipase motif (GHSLG). It controls the 
accumulation and efﬁcacy of 2-AG at the cannabinoids receptors; in fact, its 
pharmacological inhibition leads to activity-dependent accumulation of 2-AG in 
neuronal cultures. In neurones, it was found both at mRNA and protein level; in mice 
cortex, the localization of ABHD6 in neurones is post-synaptic, often juxtaposed with 
the presynaptic CB1 receptors. ABHD6 is also expressed in several principal 
glutamatergic neurones, some GABAergic inteneurones, like astrocytes but not in 
resident microglia. In murine cortical slices, inhibition of ABHD6 facilitated the 
induction of CB1 receptors-dependent long-term synaptic depression. ABHD6 inhibition 
in vivo produced CB1- and CB2-receptors mediated anti-inflammatory and 
neuroprotective effects in a mouse model of traumatic brain injury. However, after 
ABHD6 inhibition, CB1 receptor-dependent short-term synaptic depression (DSI or  
Fig.9 Regulations of 2-AG levels at the site of its generation by ABHD6 22. 
Endocannabinoid system 
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DSE) remained unaltered 
22
. 
1.4.4 ABDH12 
ABHD12 has been recently identiﬁed as a post-genomic protein, which physiological 
functions are largely unknown. Using ABPP with mouse brain proteome, its potential 
role as a brain 2-AG hydrolase was revealed and it was evaluated that ABHD12 covers 
for approximatevely 9% of total 2-AG hydrolase activity. Nowaday, 2-AG is the only 
known substrate for ABHD12 but it is possible that the enzyme utilizes also other 
substrates. ABHD12 seems to be an integral membrane, a typical a/b-hydrolase domain 
protein ﬁngerprints, including the lipase motif (GTSMG) and catalytic triad (predicted 
amino acid residues Ser
148
-Asp
278
-His
306
), are conserved either in rodent and human 
ABHD12 primary structure. Mutations in the ABHD12 gene are predicted to 
compromise catalytic activity severely, and are causally linked to a neurodegenerative 
disease called PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and 
cataract). It has been suggested that ABHD12 must act essential physiological functions 
in the nervous system and that PHARC can be considered as a human ABHD12 
knockout model. However, the possible connection to the endocannabinoid system 
clearly requires more studies. Moreover, ABHD12 transcripts are highly expressed in 
various brain regions and speciﬁcally in microglia, but are also abundant in related cell 
types such as macrophages and osteoclasts. There is also increasing interest for the 
potential role of the eCB system, and microglial CB2 receptors in particular, as 
regulators of immune function in the CNS 
22
.  
 
Fig. 10 Schematic representation of 2‐AG inactivating pathways. 2‐Arachidonoylglycerol signaling is terminated 
by MAGL, ABHD6 or ABHD12‐ mediated hydrolysis or by COX2 oxidation into PGH2‐G 16. 
Endocannabinoid system 
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In summary, even if ABHD6 and ABHD12 have a limited contribution to 2-AG 
degradation, it is possible that the different subcellular or cellular localizations of 
ABHD6 and ABHD12 compared with MAGL, might let each enzymes to access to 
distinct pools of 2-AG. New molecules like NAPE‐PLD, FAAH and MAGL have been 
discovered thanks to the characterization of the endocannabinoid biosynthetic and 
metabolic pathways; this molecules can be targeted pharmacologically not only to act 
on endocannabinoid levels, but also to clarify the role of the endocannabinoid system in 
physiological and pathological conditions. The development of more selective 
FAAH/MAGL inhibitors with in vivo activity is important to understand the specific 
biological actions of anandamide, 2‐AG and their metabolites 22,23. 
 MAGL like pharmacological target 
23 
2. MAGL like pharmacological target 
Production of arachidonic acid (AA) and glycerol from MAGL activity is involved, 
directly or indirectly, in pathological processes such as inflammation and 
carcinogenesis. There is a strong link between the endocannabinoid and eicosanoid 
pathways together through MAGL. MAGL, via hydrolyzing 2-AG, releases arachidonic 
acid, the major precursor for the synthesis of pro-inflammatory eicosanoids in specific 
tissues such as the brain, liver, and lung. Furthermore, in aggressive cancer cells, 
MAGL supplies the free fatty acids for production of protumorigenic signaling lipids. 
All together, these actions evidence the therapeutic potential of MAGL inhibitors in 
fighting a variety of human diseases through bidirectionally manipulating 
endocannabinoid, eicosanoid, and other lipid signaling pathways 
21
. 
 
Fig.11 MAGL coordinately regulates multiple lipid signaling pathways. MAGL blockade leads to an accumulation of 
the endocannabinoid 2-AG to enhance signaling upon cannabinoid receptors CB1 and CB2. In certain tissues, such as 
the brain, liver, and lung, MAGL controls the primary AA precursor pool for pro-inflammatory prostaglandin 
production. Blocking MAGL thus leads to a variety of beneficial effects through either enhancing endocannabinoid 
signaling or suppressing eicosanoid production. In cancer, MAGL plays a distinct role in controlling global FFAs 
levels that serve as the building blocks for synthesis of pro-tumorigenic signaling lipids 21. 
 MAGL like pharmacological target 
24 
2.1 The role of MAGL in pain and inflammation 
The use of Cannabis Sativa not only for recreational purpose but also for its 
therapeutical effects has been known for several years. The suppression of nociceptive 
transmission and pain behaviour in rodents is closely related to activation of 
cannabinoid CB1 receptors. However, direct activation of CB1 receptors is also 
accompany by psychoactive effects and severely constrain the therapeutic potential of 
direct acting cannabinoid agonists. Recently, a novel class of inhibitors of the 
deactivation of endocannabinoids such as anandamide and 2-arachidonoylglycerol (2-
AG) have been described. Inhibitors of fatty-acid amide hydrolase (FAAH), the enzyme 
which catalyzes anandamide hydrolysis and inhibitors of monoacyl glycerol lipase 
(MAGL), the enzyme which hydrolizes 2-AG, have been evaluated for their therapeutic 
potential for suppressing pain, anxiety and stress-related responses. Thanks to 
pharmacological studies, we can now affirm that selective FAAH and MAGL inhibitors 
produce a set of the behavioural effects seen with direct CB1 receptors agonists, 
including analgesia in multiple acute and chronic pain models. Nonetheless, neither 
FAAH nor MAGL inhibitors produce the cataleptic behavioral responses observed with 
direct CB1 receptors agonists. Moreover, in models of drug abuse, FAAH inhibitors 
have proved inactive, including drug discrimination assays. These findings indicate that 
selective blockade of FAAH or MAGL can preserve some of the beneficial effects of 
CB1 receptors activation, without maintaining the negative ones. Althought inhibitors of 
endocannabinoid metabolic enzymes produce antinociceptive and anti-inflammatory 
effects through a dual action : increasing endocannabinoid levels and reducing the 
production of arachidonic acid. 
24,25
 
The activation of immune cells such as platelets, macrophages and microglia is closely 
controlled by endocannabinoids, because it leads to the production of 2-AG. In fact, 
endocannabinoids are generally produced in response to injury, because of their 
beneficial action in decreasing proinflammatory mediators and re-establishing 
homeostasis. Thus, 2-AG (1–10 mM) inhibits proinflammatory cytokine production in 
lipopolysaccharide (LPS)-activated cultures of rat microglial cells, murine splenocytes, 
peritoneal macrophages and J774 macrophages, and has antiproliferative effects in 
lymphocytes. In activated Muller glia, the prevailing glia in the retina, 2-AG decreases 
LPS-induced cell death and proinflammatory cytokine production and enhances anti-
 MAGL like pharmacological target 
25 
inflammatory cytokine levels, in a CB1/CB2 receptors-dependent manner 
27
. Inhibitors 
of FAAH and MAGL elevate endocannabinoid levels in the brain, with prolonged 
activation of their receptor targets. It is well established that FAAH inhibitors produce 
antinociceptive effects in multiple preclinical nociceptive assays, including neuropathic, 
inﬂammatory and acute thermal nociception. While the impact of selective FAAH 
inhibition has been investigated for approximately a decade, selective inhibitors of 
MAGL have only recently been developed to examine systematically the in vivo 
consequences of elevating 2-AG levels. In 2005 it have been described the development 
of the first selective pharmacological inhibitor of MAGL, URB602. URB602 increases 
levels of 2-AG without altering levels of anandamide both in vitro and in vivo; its local 
administration into the periaqueductal grey area or into lumbar dorsal horn has been 
shown to increase levels of 2AG, but not anandamide, in the midbrain and increase non-
opioid-mediated stress-induced analgesia. This increasing of stress anti-nociception is 
associated with a profound enhancement in levels of 2-AG, but not anandamide, in the 
PAG. These evidences support the theory of a physiological role for 2-AG in 
suppressing pain and by increasing the bioavailability of endogenous 2-AG. The effects 
of MAGL inhibition are not limited to central sites: in fact, local administration of 
URB602 attenuates the late phase of the formalin response, a model of inflammatory 
pain that is instead increased with a CB2 receptor antagonist 
28
. However, because 
URB602 is less selective if it is use sistemically and it also inhibits FAAH, it is difficult 
to evaluate the real contribution of 2- AG in other districts, because anandamide has 
been shown to have the same effects in this model. More recently, the discovery of 
JZL184 allow a study of the role of 2-AG in various pathologies and the exploration of 
its therapeutic potential in a number of physiological and pathophysiological processes 
like nausea, anxiety, pain and inflammation. JZL184 dispensed in prevention or 
treatment of inflammatory pain produced by intraplantar injection of carrageenan, 
reduced the symptoms associated with inflammation (allodynia and edema) in a 
CB1/CB2 receptors-dependent manner. In trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in mice, a model of inflammatory bowel diseases (IBD), the administration of 
JZL184 increased 2-AG, but not anandamide, levels. This brings to an attenuation of all 
the symptoms of colitis. In this model, the increased circulating levels of LPS lead to a 
systemic inflammation; these high levels can also be reduced following MAGL 
inhibition that brings to a subsequent reduction in plasma cytokine levels. Anyway, 
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potent hinibitors like JZL184 leads to tolerance and a loss of efficacy with repeated 
administration 
25,26
.
 
Another inhibitor available nowadays is KML29. KML29 is known 
to be the most selective for MAGL; it does not show any detectable activity with FAAH 
even at high doses or following repeated administration, unlike JZL184. Acute or 
repeated administration of KML29 signiﬁcantly increased brain levels of 2-AG, but did 
not elevate brain anandamide levels. This compound also produced signiﬁcant anti-
allodynic and anti-oedematous effects in the carrageenan model of inﬂammatory pain. 
Significantly, KML29 did not causes THC-like effects and did not produce 
cannabimimetic effects. The antinociceptive effects of KML29 were mediated through 
distinct cannabinoid receptor mechanisms of action. The anti-oedematous action in the 
carrageenan model of neuropathic pain is not present in CB2 receptors (−/−) mice; in 
this model, KML29 partially reversed mechanical allodynia and strongly reversed cold 
allodynia through a CB1 receptor mechanism. This confim that CB1 receptors, not CB2 
receptors, mediated the antinociceptive properties of KML29 in neuropathic pain. 
However, both CB1 and CB2 receptors were required for the anti-allodynic effects of 
KML29 in inflammatory pain. CB2 receptor component in the anti-allodynic effects of 
MAGL inhibition in the various inﬂammatory pain models could be associated to 
infiltration of immune cells, which present a high CB2 expression. Differently, the CB1 
receptor component may be mediated by activation of these receptors located 
supraspinally, spinally or in peripheral nociceptors. It is well known that the 
antinoceptive effect of endocannabinoids involves both supraspinal structures (e.g. 
periaqueductal gray, thalamus, rostral ventromedial medulla and amygdala), and the 
dorsal horn of the spinal cord. In the CNS, MAGL is localized mainly presynaptically 
and it is also expressed in microglia. Endocannabinoids are produced in dorsal root 
ganglion cells, a primary afferent input to spinal cord. However, anatomical localization 
of MAGL in the periphery is not known. Thus, the antinociceptive effects of MAGL 
inhibitors in pain models involving a strong inﬂammatory component, may involve both 
neuronal and non- neuronal sites of action, within the CNS and periphery 
25,27,29
. 
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Fig. 12 Connecting cannabinoid and prostaglandin pathways: inhibition of MAGL (a) increased the levels of 2-
arachidonoylglycerol (2-AG) in the brain, which added through the cannabinoid receptors to decrease pain (b) 
and lowers the production of arachidonic acid to decrease levels of inflammatory prostaglandins and blunt 
inflammation in the brain (c) 30. 
 
2.1.1  Relation between MAGL and Cyclooxygenase 
There is a strong correlation between MAGL and cyclooxygenase enzymes (COX); in 
fact, the positive effects of selective MAGL inhibitors such as antinociceptive and 
gastroprotective effect, are attributable to FAAH and MAGL enzymatic activity itself, 
since they hydrolyze their respective substrates, anandamide and 2-AG, producing 
arachidonic acid, which is the substrate of COX enzymes. 
 
Fig. 13 Interconnections between COX-2 and MAGL/FAAH catalytic activity 31. 
 MAGL like pharmacological target 
28 
Cyclooxygenase (COX) enzymes, also known as prostaglandin H synthases, catalyze 
the conversion of arachidonic acid (AA) in the biosynthetic precursor of prostaglandins 
and tromboxane, prostaglandin H2 (PGH2). These lipids mediate several physiological 
and pathophysiological effects, like pain, fever, inflammation, hemostasis, regulation of 
renal function and maintenance of mucosal integrity in the stomach. There are two COX 
isoforms, COX-1 and COX-2; they are homodimers with a molecular mass of 
approximately 70 kDa per monomer, with a similar tertiary and quaternary structures, 
and 65% amino acid sequence homology and near-identical catalytic sites
 32
. The 
difference between the two enzimes was discovered thanks to tha analysis of the 
nonconserver residues of the binding pockets: in fact, Ile
523 
 of COX-1 is substituted by 
a valine in COX-2. The smaller Val
523
 residue in COX-2 allows access to 
a hydrophobic side-pocket in the enzyme (which Ile
523
 sterically hinders); this explain 
the ligand selectivity. COX-1 is the constitutively isoform, expressed in mammalian 
tissues and cells (its concentration in the body remain stable), while COX-2 is the 
inducible isoform and is generally present in mammalian tissues at very low levels, 
unless enhanced by many types of stimuli like cytokines and growth factors. The 
production of prostaglandins G2 and PGH2 starts with the conversion of arachidonic 
acid (or other 20 carbon fatty acids), catalysed by COX; PGH2 is subsequently 
converted to a variety of eicosanoids that include PGE2, PGD2, PGF2α, PGI2, and 
thromboxane (TX) A2 
33,34
. Prostaglandins play a key role in the generation of the 
inflammatory response. Their biosynthesis is significantly increased in inflamed tissue 
and they contribute to the development of the cardinal signs of acute inflammation. 
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Fig.14 The arachidonic acid cascade. COXs produce PGH2 from AA in two chemical reactions: the first step is the 
addition of two moles of oxygen to arachidonic acid to generate PGG2; this is followed by a peroxidase reaction, 
which reduces PGG2 to produce PGH2. These chemical reactions are made in two distinct active sites of the COXs. 
Moreover, COX enzymes also generate minor quantity of HETEs (mono-oxygenated metabolites of AA) 32. 
 
Prostaglandin E2 (PGE2) is a crucial mediator of inflammatory pain sensitization and in 
modulation of the integrity of the gastrointestinal mucosa; it is produced both in 
peripheral inflamed tissues and in the spinal cord. PGE2 acts on a group of G-protein-
coupled receptors, which are divided in four subtypes: PGE2R1, PGE2R2, PGE2R3 and 
PGE2R4. Prostaglandin E2 signaling causes several alterations in synaptic transmission 
in the spinal cord dorsal horn, playing a key role in the development of inflammatory 
pain; indeed, the spinal cord dorsal horn is the first site of synaptic integration in the 
pain pathway, that includes peripheral nociceptors, which make synaptic contacts with 
local excitatory and inhibitory interneurons and central projection neurons; these 
neurons have to convey nociceptive information to higher central nervous system areas. 
PGE2 signaling can enhance the responsiveness of peripheral nociceptors that generate 
excitatory glutamatergic transmission 
35
.  
Recent reports demonstrated that 2-AG levels are also controlled by cyclooxygenase 
(COX)-2 activity; the interference with 2-AG, although it is a bioactive lipid in itself, 
blocks the production of several other bioactive lipids which come from 2-AG. 
Whereby, MAGL activity is a key performer in the control of arachidonic acid tissue 
levels, and thus in the production of prostaglandins during inflammation in several 
tissues such as brain, liver, lung. Nearby COX- 2, some lipoxygenases (LOXs) are also 
responsible for the oxidation of 2-AG: 12-LOX generates 12(S)-hydroperoxyeicosa- 
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5,8,10,14-tetraenoic acid glycerol ester (12-HETE-G), and 15-LOX produces the 
peroxisome proliferator-activated receptor (PPAR)a agonist 15-HETE-G. These facts 
demonstrate the close relationship between the endocannabinoid and eicosanoid systems 
27
. 
 
 
Fig.15 2-Arachidonoylglycerol (2-AG) metabolism at the crossroads of the endocannabinoid and eicosanoid systems 
27. 
 
The dual metabolism of endocannabinoids (hydrolysis into AA by specific lipases and 
their COX-2-mediated oxygenation) puts forth a bilateral interaction between the 
endocannabinoid and eicosanoid systems. Even if endocannabinoids show anti-
inflammatory effects, 2-AG is a big source of arachidonic acid in the brain, and several 
effects of inhibiting endocannabinoid hydrolysis and enhancing their levels were 
attributed to the following decrease in AA and the consequently blocking of the PGs 
pathway. Moreover, the inhibition of PG synthesis by a reduction in AA availability is 
not the only process caused by COX-2 inhibition, but there are other implications such 
as the inhibition of endocannabinoid metabolism and the activation of the cannabinoid 
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receptors. Several studies support this hypothesis: COX-2 is constitutively expressed in 
the brain, where influences endocannabinoid metabolism and control endocannabinoid-
mediated effects on GABAergic transmission; antinociceptive effects of NSAIDs and 
COX-2-selective inhibitors in mice pain models can be blocked by a CB1 receptor-
selective antagonist; COX inhibitors can enhance endocannabinoid levels in murine 
models of inflammation. This carries to the hypotesis that studing the endocannabinoid 
component of COX-2 inhibition might be a method to increase the effects of NSAIDs 
and reduce their toxicity; in fact, the efficacy of NSAIDs in painful and inflammatory 
deseases is offsetted by numerous studies pointing the role for COX-2 in the resolution 
of inflammation, and the increasing risk of gastrointestinal and cardiovascular events 
with the use of COX inhibitors. Considering the structure of COX enzymes, COX-2 
does not need a free carboxyl group in the substrate, as COX-1 does; this fact lets COX-
2 metabolize neutral derivatives of AA such as esters and amides. It was shown that 
COX-2 can oxidize 2-AG with a similar efficiency as for AA. However, nowaday it has 
not been yet discovered which amino acid residue is crucial and selective for this 
activity: it seems to be implicated the Arg
513
, but there is not a strong evidence. COX-2-
mediated oxygenation of 2-AG brings to the production of PG-Gs: PGD2- G, PGE2-G, 
PGF2a-G and PGI2-G. The effects of these compounds are not totally clear, but it is 
possible to adfirm that they are distinct from the effects of the corresponding 
prostaglandins and probably differ from one PG-G to the other. For example, PGE2-G 
in cultured macrophages mobilizes calcium, activates signal transduction and modulates 
nuclear factor (NF)kB activity; furthermore, PGE2-G causes hyperalgesia in 
carrageenan-induced inflammation, and this effect is only partially blocked by 
antagonists of prostanoid receptors. Several studies demonstrated the extension of the 
production of PG-Gs in various inflammatory settings in vivo and their effects. 
Moreover, thanks to the different expression of prostaglandin synthases in various 
tissues, different PG-Gs are produced according to distincts tissues or conditions; these 
studies want to explore the endocannabinoid component (increased levels of 2-AG) of 
COX-2-based therapies, that might bring to a reduction of the doses to get the anti-
inflammatory effect; could be interesting the association of an NSAID with a compound 
inhibiting endocannabinoid degradation for the synergic action, to open up new 
therapeutic pathways 
27,36,37
. 
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2.2 Role of MAGL in neurodegenerative deseases 
Nowaday, it is well established that inflammation is a big component of several 
neurological disorders, including chronic pain, traumatic brain injury, 
neurodegenerative diseases like Parkinson's and Alzheimer's. In the nervous system the 
inflammatory process is supported by the activity of COX (COX-1 and COX-2), 
localized in neurons and glial cells, that mediate the conversion of arachidonic acid to 
prostaglandins. Phospholipase A2 (PLA2) enzymes, and cytosolic PLA2 (cPLA2) in 
particular, are the principal source of arachidonic acid for prostaglandin production; 
however, cPLA2-deficient mice have unaltered AA levels in brain. Moreover, the 
inactivation of MAGL in mice highly decreases AA levels. These facts evidence that 
there are different mechanisms which regulate the production of prostaglandins in the 
nervous system 
22,25
. Moreover, 2-AG acts as a retrograde messenger in regulation or 
modulation of synaptic transmission and plasticity, with anti-inflammatory and 
neuroprotective properties , and promoting neurogenesis. Several evidences reveal that 
a large proportion of prostaglandins, which are the most important mediators in synaptic 
plasticity, inflammatory response and neurodegenerative diseases, derives from 
metabolites of 2-AG by MAGL. Thus, MAGL is crucial in regulating endocannabinoid 
and prostaglandin signaling, suppressing neuroinflammation, preventing 
neurodegeneration against harmful insults, maintaining homeostasis of brain function 
and enhancing long-term synaptic plasticity, through CB1 receptor-mediated 
mechanisms 
38
.  Genetic and pharmacological block of MAGL exhibit anti-
inflammatory effects in the brain and neuroprotective effects in mouse models of 
Parkinson's disease and Alzheimer's disease. Inactivation of MAGL suppress LPS-
induced pro-inflammatory cytokine release and microglial activation, lowering 
neuroinflammatory eicosanoid production, and not through CB1 or CB2- receptors 
dependent mechanisms. In an MPTP model of Parkinson's disease, MAGL blockade 
with JZL184 or MAGL deficiency protects against dopaminergic neurodegeneration 
and dopamine loss, in according to the suppression of pro-inflammatory eicosanoids. 
Several efforts have also discovered elevated levels of endocannabinoids and 
eicosanoids in the brains of a presenilin/amyloid precursor protein (PS1/APP+) mouse 
model of Alzheimer’s desease: MAGL inactivation reduces  eicosanoid levels in the 
Alzheimer’s desease mouse model, in according to the suppression of astrocyte and 
microglial activation and reduction of cytokines, carrying to a considerable decrease in 
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amyloid plaques. There is a low cannabinoid component in the protective response seen 
with MAGL inhibitors in the Parkinson's disease or Alzheimer’s desease mouse models; 
this can be connected to the functional desensitization of the cannabinoid system over 
chronic MAGL blockade 
39
. In multiple sclerosis, the anti-inflammatory properties of 
cannabinoids are associated with a decreased number of activated microglia in the 
spinal cord, reduced expression of major histocompatibility complex class II, and 
decreased number of CD4+ Tcells. Activated microglia and other immune cells that 
invading the nervous system are responsable of the release of toxic cytokines and free 
radicals in multiple sclerosis, which represent a big portion of the neurodegenerative 
damage; this effects can be decreased with the action of endocannabinoids, by inhibiting 
inflammation, exerting an indirect neuroprotective action. The direct neuroprotective 
action of endocannabinoids, however, involves CB1 receptors: their action limit 
glutamate release and excitotoxic damage in several neurodegenerative disorders. Most 
of this damages are also present in amyotrophic lateral sclerosis, that is a severe 
neurodegenerative disorder that selectively damages upper and lower motorneurons; 
such as in multiple sclerosis, the action of endocannabinoids decreases glutamate 
release from presynaptic terminals, leading to the protection against neuronal death 
induced by glutamate through pre- and postsynaptic mechanisms 
40
. 
 
2.3 The Role of MAGL in cancer and cancer-related  
symptoms   
Cancerous cells result from the transformation of normal cells through several changes 
which occurs in original metabolic pathways, such as the regulation of glycolysis, 
glutamine dependent anaplerosis, and the production of lipids. Nowaday, even if it is 
well established  that dysregulated metabolism is a foundamental feature of cancer, it is 
not clear how biochemical changes occur and if they are crucial in disease progression 
and malignancy. Several studies have confirmed that encreased de novo lipid 
biosynthesis, or the development of a ‘‘lipogenic’’ phenotype, has been posited to play 
a major role in cancer. Accordingly, it has been shown that elevated levels of fatty acid 
synthase (FAS), the enzyme that catalyzes the fatty acid biosynthesis from acetate and 
malonyl CoA, are linked with poor prognosis in breast cancer patients. The inhibition of 
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FAS leads to a reduced cell proliferation, loss of cell viability, and reduced tumor 
growth in vivo. FAS may promote cancer growth by supplying metabolic substrates for 
energy production, via fatty acid oxidation 
41
. Moreover, there are also other 
characteristics of lipid biochemistry  which are indispensable for the malignancy of 
cancer cells, including the production of building blocks for newly synthesized 
membranes to promote high rates of proliferation 
42
; the composition and regulation of 
membrane structures that coordinate signal transduction and motility, like lipid rafts, 
invadopodia, blebs 
43
; the biosynthesis of a set of protumorigenic lipid-signaling 
molecules. Some examples of lipid messengers that are involved in cancer are 
phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3], which activates protein kinase 
B/Akt to promote cell proliferation and survival; lysophosphatidic acid (LPA), which 
stimulate cancer aggressiveness through a family of G protein-coupled receptors; 
prostaglandins formed by cyclooxygenases, which facilitates migration and tumor-host 
interactions 
41
. These evidences correlates MAGL to its action in cancer growth. In fact, 
MAGL was initially known for its role in hydrolysis of monoacylglycerols from stored 
triacylglycerols to generate free fatty acids and glycerol. This is a crucial process for 
generating precursors for lipid and membrane synthesis or lipid signaling mediators. 
Initially, the regulatory role for MAGL in lipolysis was not considered because of the 
limiting step in the process, the action of hormonesensitive lipase (HSL); adipocytes of 
HSL-deficient mice accumulate DAG in several tissues indicating that HSL is rate-
limiting for DAG hydrolysis, and consequently for monoacylglycerols 
44
. Only recently 
it has been reported that the alterated lipolytic pathway in human cancer involves 
MAGL, which is highly expressed in aggressive human cancer cells and primary tumors 
including. Several studies demonstrated, with pharmacological or genetic inhibition, 
that MAGL is also linked to high proliferation, invasiveness, and in vivo tumor growth. 
For example, MAGL is overexpressed in colon carcinoma, and its levels are correlate 
with body mass index, that is a negative prognostic factor in colon and other cancer 
types. Moreover, it is also elevated in androgen-independent prostate cancer cells. The 
tumor-promoting action of MAGL is caused by an increase in free fatty acids, 
particularly C16:0 and C18:1. The increased free fatty are coverted into oncogenic lipid 
mediators by several enzymes, like acyltransferases and cyclooxygenases, which are 
part of a tumorigenic network, togheter with MAGL. This is another reason to focus the 
research efforts on synergic action both on MAGL and COX. 
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                                            Fig. 16 Metabolic pathways of production of free fatty acids 47. 
 
To understand the central role of MAGL in control free fatty acids, the treatment with 
the FAS inhibitor C75 did not reduce FFA levels in cancer cells, suggesting the close 
relationship between FFA and MAGL. Several studies demonstrated that  aggressive 
cancer cells acquire the ability to liberate FFAs from neutral lipid stores as a 
consequence of encreased expression of MAGL. MAGL and its FFA products were 
found to be elevated in aggressive human cancer cell lines from multiple tissues of 
origin; further evidence in support of this premise originates from gene expression 
profiling studies, which have identified increased levels of MAGL in primary human 
ductal breast tumors compared to less malignant medullary breast tumors. Furthermore,  
a potential role of increased endocannabinoid tone in the antitumor effects of MAGL 
cannot be excluded, because of the pharmacological evidence of the tumor-inhibiting 
properties of cannabinoid receptor agonists. For example, in prostate cancer the 
antitumor effects of MAGL inhibition were totally cancelled by cotreatment with fatty 
acids and the CB1 receptor antagonist SR141716, demonstrating that an enhanced 
endocannabinoid signaling and a decreased provision of free fatty acids from MAGL 
enzymatic hydrolysis contribute to the antitumor effect observed. Because cannabinoids 
agonists show a large spectrum of palliative properties in cancer, MAGL blockade 
could be an interesting strategy for attenuating cancer-associated symptoms. Both 2-AG 
administration and MAGL inhibition reduce nausea and vomiting in mice models and 
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decrease mechanical hyperalgesia in a mouse model of bone cancer pain. Nevertheless, 
long-term increases in 2-AG levels in the nervous system induced by JZL184 and by 
MAGL genetic silencing cause CB1 receptors downregulation and tolerance to 
cannabinoid agonists and to the MAGL inhibitor itself. Furthermore, in tumors of the 
brain, such as gliomas, in which enhanced endocannabinoid tone has protective and 
proproliferative effects MAGL inhibition could be injurious, as well as in hematological 
malignancies, because hematopoietic cells and progenitor cells migrate in response to 2-
AG 
45,46,47
. 
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3. Monoacylglycerol lipase (MAGL) 
 
3.1 MAGL: structure and most important residues 
 MAGL was first isolated and cloned from adipose tissue, where it was characterized as 
an enzyme responsible for the last step of triglyceride catabolism. Since its first 
identification, MAGL localization has been extended to many other tissues, and it is 
now known that this serine hydrolase constitutes an ubiquitously expressed enzyme. In 
mouse, high levels of mRNA MAGL were found in adipose tissue, kidney and testis; 
high levels of MAGL expression have been also individuated in other organs, like 
adrenal gland, brain, heart, lung, skeletal muscle, liver, ovary and spleen. In the brain, 
MAGL transcript is also present ubiquitously (cortex, hippocampus, cerebellum, 
thalamus, striatum), even if lower levels of mRNA were found in brain stem and 
hypothalamus
 48
. MAGL is a seryne hydrolase with a molecular weight of ~33 kDa, 
with a high degree of amino acid sequence homology among human, mouse, and rat. 
The crystal structure of MAGL was  solved and this was obtained independently by two 
laboratories. The protein folds conserved in the α/β hydrolase superfamily were present 
also in the MAGL structure. These include an eight-stranded β-sheet, formed of seven 
parallel strands and one antiparallel strand, surrounded by α helices. Furthermore, a 
ﬂexible cap domain covers the structurally conserved β-sheet and a cap domain 
preserves the entrance of a relatively large, occluded hydrophobic tunnel (approx. 25 A 
in length and approx. 8 A ˚ in width). The active site is buried at the bottom of the 
tunnel 
21,22
. The cap domain seems to act as a lid, let the enzyme to unveil its otherwise 
unreachable hydrophobic active sites when  the protein come into contact with lipid 
droplets. This process has been termed “interfacial activation”, and thereby allows the 
enzyme to exist in two main conformational states, a closed and an open form (authors 
suggested the hypothesis that the enzyme naturally adopts an open conformation in 
solution) 
49
. 
 
 Monoacylglycerol lypase (MAGL)  
38 
 
Fig.17 Structure of MAGL. A) MAGL asymmetric unit. a4 helix is colored magenta. Membrane representation is a 
palmitoyloleoylphosphatidylethanolamine bilayer minimized using molecular dynamics simulation.[47] B) Left: Side 
view of a MAGL monomer, with catalytic triad represented as sticks, and cap domain colored magenta. Right: Top 
view (908 rotation) of the same MAGL subunit 49. 
 
The catalytic triad is made up of residues Ser
122
, Asp
239
 and His
269
. The tridimensional 
structure therefore provides the first evidence of the identity of this catalytic triad, 
previously reported based on mutagenesis studies. The Ser
122
 is located in the GXSXG 
consensus sequence, between helix α3 and strand β5, in the “nucleophilic elbow” sharp 
turn found within this superfamily. This model also suggested that two cysteine residues 
(C208 and C242) were located within a close distance from the active site and  both 
these cysteines can be involved in binding processes 
49
. 
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3.2 Binding of the natural substrate 
 
Informations about MAGL structure offer the first structural basis for rational drug 
design. To explain MAGL activity and understand some key structural features of the 
active site, the docking of MAGL with 2-AG has been done, to simulate the tetrahedral 
intermediate state, covalently bound to Ser
122
. This unveils a cavity capable to hold the 
long and flexible lipid chain of the substrates. If the substrate moves away from the 
catalytic triad (Ser 
122
, Asp 
239
, His 
269
 ), which is deep in the protein, to the  surface of 
the protein,  the cavity becomes larger  (Fig. 18) 
49
. 
    
 
Fig.18  Docking of 2-AG in the active site. The natural substrate is bound in the tetrahedral intermediate state to 
Ser122. The four conformations discovered by using Gold software are shown using different colours. A) Acyl-
binding and B) alcohol-binding sites and  C) the glycerol exit channel are evidenced. Side chains of residues 
interacting with the 2-AG acyl moiety or lining the hydrophilic cavity are represented as sticks. The interactions in 
the oxyanion hole are highlighted with dashed lines. The a4 helix is also indicated by arrows 49. 
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Some hydrophobic residues recover the channel carrying from the surface to the 
nucleophilic serine. In fact, Leu
148
, Ala
164
, Leu
176
, Ile
179
, Leu
205
, Val
207
, Ile
211
, Leu
213
, 
Leu
214
, VaL
217
 and Leu
241
 side chains are opportunely located to interact with the 
arachidonoyl portion of 2-AG, and mediate the MAGL substrate specificity for lipid 
substrates. The close region of the catalytic triad shows a more hydrophilic character 
than the channel pointing to the enzyme surface. Close to the backbone NH from Met
123
 
and Ala
51, which form the “oxyanion hole,” the Tyr58 hydroxyl group, the NH from the 
His
121
 and His
272
 side chains, the guanidinium from Arg
57
, the carboxylate from Glu
53
, 
and the backbone carbonyl from Ala
51
 border a polar cavity that holdes the polar 
glycerol head group of 2-AG. In support of the proposed binding mode of 2-AG, a 
glycerol molecule has been found in this alcohol-binding pocket. In the vicinity of the 
oxyanion hole, at the end of the structure-refinement process, there is a positive electron 
density feature. This was located at the entry of this polar cavity and exactly at the same 
place as the glycerol region in 2-AG docking results (fig.19). The glycerol alcohol 
region interacts with the Ala
51
 carbonyl group, Tyr
194
 alcohol and Glu
53
 carboxylate. 
The His
121
 lateral chain and a conserved water molecule inside the cavity are located 
near to the alcohol and so can also interact with the glycerol function and participate to 
the MAGL selectivity for monoacylglycerols 
49,50
.  
 
Fig.19  Electron density in the MAGL active site. A glycerol molecule is bound in the alcohol-binding pocket 49. 
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3.3 MAGL catalytic mechanism 
MAGL shares the common mechanism of the lipolytic enzymes, which consists of two 
steps:  
- The enzyme interacts with the lipid-water interface (stage bonding).  
- The substrate is received in the catalytic site, where with an acid-base reaction, which 
involves the nucleophilic attack of the catalytic serine activated hydroxyl group on the 
substrate activated carbonyl carbon, the ester bond is hydrolyzed. The initial step of the 
mechanism is the protonation of the His
269
 in the active site from the serine residue. 
Histidine protonation is stabilized by the negative charge associated with Asp
239
, the 
third residue of the MAGL catalytic triad, which is in a hydrophobic region. In this 
manner, the catalytic Ser
122
 becomes a strong nucleophile and attacks the carbonyl 
carbon of the substrate with the formation of a tetrahedral intermediate that is stabilized 
by the oxyanion hole; this is responsable of the activation of the carbonyl group of the 
substrate. When the tetrahedral intermediate (His
269
, Ser
122
, Asp
239
) is formed, the 
mechanism of action of the enzyme improves, with the acylation of the serine and the 
elimination of the leaving group. (Fig 20). The enzyme can return to the active form 
only when a water molecule attacks the active site, favoring the deacylation of serine 
and allowing MAGL to repeat the hydrolytic process 
49,50,53
. 
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Fig. 20 General catalytic mechanism of seryne hydrolases 53. 
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4.  MAGL inhibitors  
 
Monoacylglycerol lipase (MAGL) hydrolyzes and degrades the endocannabinoid 2-
arachidonoylglycerol (2-AG), with the release of arachidonic acid (AA), which is the 
major precursor for the synthesis of pro-inflammatory eicosanoids in specific tissues, 
such as the brain, liver and lung. Moreover, MAGL provides the pool of free fatty acids 
for production of protumorigenic signalling lipids in aggressive cancer cells.  
Consequently, inhibition of MAGL, which results in enhanced 2-AG levels, carries to 
some beneficial therapeutic effects, like attenuation of pain, anxiety, nausea, 
inflammation, neurodegeneration, precipitated opioid withdrawal responses, and cancer 
pathogenicity. These data suggest that MAGL is a potential target for the development 
of new drugs 
52
. 
 
4.1  General serine hydrolase inhibitors 
Only in recent years have become available selective pharmacological compounds able 
to block MAGL activity. They allowed to demonstrate the role of this enzyme in 2-AG 
signaling termination. MAGL activity is sensitive to general serine hydrolase inhibitors 
like methyl arachidonoylfluorophosphonate, PMSF, arachidonoyl 
trifluoromethylketone, and hexadecysulfonylfluoride. Nevertheless, these compounds 
also inhibit FAAH and are thus not appropriate to discriminate the function of these 
enzymes. Therefore, it is necessary to focus the attention on the research of structural 
essential features to inhibit selectively MAGL over FAAH, also because of their 
similarity in  the enzymatic mechanism and in the substrate structure 
53
.  
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Tab.1  General non-selective Serine hydrolase inhibitors 53. 
Several studies have demonstrated that MAGL, differently from the other serine 
hydrolase,  is also inhibited by general sulfhydryl-specific agents, including p-
chloromercuribenzoic acid, mercury chloride, and N-ethlymaleimide, indicating the 
presence of a critical free cysteine residue.  
All the compounds that can inhibit MAGL are differentiated into reversible and not 
reversible in terms of type of interaction with the enzyme. The first generation of 
functional MAGL inhibitors, from the more to the less selective, includes several 
compounds
 51,53
. 
4.1.1  The carbamate compound URB602 
 URB602 ([1,10-biphenyl]-3-yl-carbamic acid, cyclohexyl ester) is a selective and 
noncompetitively  MAGL inhibitor with relatively low potency; moreover, it doesn’t 
affect the activities of lipid-metabolizing enzymes such as diacylglycerol lipase and 
cyclooxygenase-2. When URB602 is microinjected in the rat periaqueductal gray 
matter, it produces a moderate enhance in the concentration of 2-AG, but not of 
anandamide, and increased stress-induced analgesia. Its systemic administration in vivo 
is limited because of his modest potency; moreover, his selectivity is not totally 
adfirmed because it has been shown to be equally potent against FAAH in vitro. 
However, URB602 has been shown to attenuate nociception in rodent models of acute, 
inflammatory, and neuropathic pain 
51,54
. 
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Fig.21 The carbamate compound URB602 51. 
In 2011, the crystal structure of MAGL was used in the structure design strategy, 
considering the three possible binding sites for URB602 in the enzyme.  Several 
carbamate analogues were docked into the three sites to discover the most importants 
binding location, exploring the effects of isosteric replacement, ring size and 
substitution, para substitution of the biphenyl moiety and the incorporation of a bicyclic 
element. The compounds were tested, but the results were poor: the carbamate that 
showed the most significant activity inhibits MAGL to 26% of controls at 100 µM 
compared to 73% for the parent compound URB602 
55
. 
 
4.2 Inhibitors Inspired by the Endogenous 
Substrate 
4.2.1  2-AG analogues 
In the structure of the endocannabinoid 2‐AG we can individuate three main regions 
susceptible to modifications: fatty acid chain, linker and glycerol moiety. 
 
Fig.22 Point of structural modifications in 2-AG 53. 
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According to these evidences, several studies tested the capacities of a series of 
analogues of 2‐AG (Table 2) in their ability to inhibit cytosolic MAGL activity. With 
respect to the fatty acid chain, the experimental data reveal that both isomers 2‐AG and 
1‐AG are equipotent in blocking  MAGL activity (IC50 = 13 and 17 μM, respectively) 
22,53
. 
 
 
Tab.2 inibition of FAAH and MAGL by 2-AG analogues 53. 
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Among the derivatives of first generation inspired by the 2-AG, stand out for their 
activity: 
N-Arachidonoyl maleimide NAM: is an irreversible MAGL inhibitor that reduces 2-AG 
hydrolase activity of rat cerebellar membranes by ̴ 90% and encreases the effects of the 
exogenous administeretion of 2-AG. Even if NAM is relatively selective for MAGL 
compared to other serine hydrolase enzymes, including FAAH, NAM’s maleimide 
group is a general thiolreactive electrophile that will react with many cysteine-
containing proteins in vivo, restricting its use in physiologic studies 
51
.   
 
Fig.23 NAM 51. 
The tetrahydrolipostatin derivative OMDM169: OMDM169 inhibits MAGL and 
pancreatic lipase with 10-fold selectivity over FAAH and the 2-AG biosynthetic 
enzyme DAGLa in vitro. Systemic administration of OMDM169 in mice decreased the 
expression of nociceptive behavior in the second phase of the formalin test and 
moderately elevated 2-AG levels in the formalin-treated paw, but not in the brain 
51
. 
 
Fig. 24 OMDM169 51. 
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4.2.2  1-AG Homologues  
A group of analogues of 1-AG have been studied as MAGL inhibitors because of 1‐AG 
comparable potency to 2‐AG as MAGL inhibitor (IC50 (1‐AG) = 17 μM and IC50 (2‐
AG) = 13 μM) and his more stability in biological solutions. The structural study (Table 
3) includes variations in length (14‐22 carbons) and number of unsaturations (0‐5) of 
the fatty acid chains. The main conclusions indicate that for cytosolic MAGL the 
number of unsaturations does not influence significantly the interaction as the IC50 
values range between 4.5 and 21 μM. However, a decay of inhibition is observed for the 
monounsaturated compounds (O3908 and O4066) and a total loss of activity for the 
saturated C‐20, 1‐arachidinoylglycerol. In contrast, shorter fully saturated compounds 
such as 1‐palmitoylglycerol (C‐16) and 1‐myristoylglycerol (C‐14) inhibit MAGL 56. 
 
Tab.3 inhibtion of FAAH and MAGL by a series of 1-AG analogues 53. 
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4.3 De Novo inhibitors 
4.3.1 Carbamate function 
Recently a novel selective and in vivo-active MAGL inhibitor, the piperidine carbamete 
JZL184, has been developed. It permits to demonstrate MAGL’s role in 2-AG signaling 
termination and the potential use of targeting MAGL in the treatment of nervous system 
disorders. JZL184 is a piperidine carbamate that inhibits MAGL with an irreversible 
carbamoylation of the enzyme’s catalytic serine; this compound lets to undestand the 
importance of the carbamate reactive group as a privileged scaffold for serine hydrolase 
inhibitor design. JZL184 is relatively selective for MAGL against other mouse brain 
serine hydrolases and shows  ̴ 100-fold selectivity to this enzyme over FAAH. MAGL 
blockade by JZL184 reduced 2-AG hydrolysis in mouse brain membranes by 85%;  a 
single injection of JZL184 can inhibit  MAGL in the mouse brain for 24 hours without 
altering anandamide levels. However it has been shown, at cerebral level, that JZL184 
displays a partial activity against FAAH when administered at high doses or 
chronically, resulting in a modest enhance of anandamide, while at the peripheral level, 
it has been observed that JZL184 can inhibit, like other carbamate derivatives, different 
enzymes of the endocannabinoid system.  
 
Fig.25 JZL184 51. 
Despite this, JZL184 is the first example of how the carbamate is a key moiety for the 
design of new potent and selective inhibitors 
51,57
. 
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4.3.2 Fluoro derivates 
O-Hexafluorisopropyl Carbamates, like KML29: Recently, the next-generation of 
MAGL inhibitors is based on an O-hexafluoroisopropyl carbamate scaffold that have 
superior selectivity to MAGL against other serine hydrolases in the brain and peripheral 
tissues. The O-hexafluoroisopropyl analog of JZL184, KML29, conseves the same 
potency toward MAGL, but improving selectivity over FAAH and CES enzymes both 
in vitro and in vivo. In mice, KML29 dose dependently blocks MAGL and elevated 
brain 2-AG levels without inhibiting FAAH activity, even when it is dosed chronically. 
Moreover, KML29 manteins much of its characteristics for both rat and human MAGL 
orthologs. In rats, KML29 inhibited MAGL by 90% and increased brain 2-AG levels 10 
times without envolving anandamide levels 
58
.  
 
Tab. 4 Values for JZL184 and KML29 against mouse, rat and human orthologs 58. 
 
Thus, it represents a versatile inhibitor to investigate MAGL function in human cell and 
rodent models under both acute and chronic dosing regimens 
51,58
.  
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Fig. 26 KML29 51. 
Derivate triazolocarboxamide SAR629: it is a derivative of the triazolo-carboxamide 
series; it shows a nanomolar activity range, in according to that of other carbamate-
containing compounds. 
 
Fig.27 SAR629 50. 
SAR629 mechanism of inhibition mimics the pathway of 2‐AG MAGL-mediated 
hydrolysis by making a relatively stable carbamate adduct with the catalytic serine 
instead of the relatively labile ester adduct 
50
. 
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Fig. 28 a) hydrolysis of 2‐AG by MAGL. b) hydrolysis of SAR 629 by MAGL 50 
In the analysis of model in which SAR629 and MAGL bound covalently, the compound 
adopts a Y shape with its two fluorophenyl moieties pointing toward opposite directions 
and perpendicular to each other (Fig.29).                                                                                                                                                           
 
Fig.29 Pharmacophoric model of SAR629 and JZL184. (Dark green elements depict flat and hydrophobic 
pharmacophoric points, whereas the orange element depicts a polar pharmacophore. Ar, aromatic) 50 
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These portions are perpendicular to the piperidine linker that adopts a chair 
conformation. SAR629 interacts with MAGL by hydrophobic interactions and few polar 
interactions, in addition to the covalent bond with Ser
122
 . Water‐mediated interactions  
occur between the inhibitor nitrogen piperazine or oxygen atoms of its carbamate 
function and His
269 
side‐chain or Ala61 main‐chain carbonyl oxygen (Fig. 30). 
 
 
Fig. 30  A) Docking study of SAR629 into the active site of the enzyme, B) van der Waals interactions of the 
piperazine moiety 50. 
 
The role of the piperazine is to orient the other moieties toward pharmacophoric points, 
and it could probably be replaced by other substituents. The indicated MAGL inhibitor 
JZL184 has a chemical structure very close to that of SAR629 (Fig. 29). 
 Its mechanism of inhibition and its mode of recognition should be similar (Fig. 29/ Fig 
31) 
50
. 
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Fig. 31  Hydrolysis of JZL184 by MAGL 
 
 
4.3.3 Inhibitors Targeting the Essential Sulfhydril Group of 
MAGL 
 
The presence of some thiol groups near to the catalytic site of the enzyme bring to the 
design of N-ethylmalemide as MAGL inhibitors (Tab. 5) 
59,60
.  
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Tab.5 Inhibition of MAGL by maleimide and succinimide derivates in rat cerebellar membranes 53. 
 
Recently, a compound already known, the Disulfiram, employed in the past for 
treatment against alcoholism, has been found to inhibit MAGL with micromolar 
affinity. Therefore, a series of MAGL inhibitors based on this template has been 
developed. The most potent representative, bis(4-methyl-1-piperazinylthiocarbonyl) 
disulfide, displayed an IC50 of 110 nM on the pure enzyme, and a more than 1000 
selectivity ratio for MAGL compared to FAAH 
61
.  
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Fig.32 Derivates used in alcoholism treatment. 
 
4.3.4 Organophosphoric (OP) Derivatives as MAGL 
Inhibitors 
Organophosphorus (OP) derivatives with general structure showed in figure 33, are 
another class of potential MAGL inhibitors and could interact with several components 
of the cannabinoid system. 
 
Fig.33 General structure of OP derivates 
 
Casida et al. adfirmed that some OP derivatives inhibit MAGL activity in vitro, leading 
to elevation of 2‐AG levels in mice brain, moreover they displayed that most OP 
compounds possess no selectivity for MAGL versus FAAH. One of the most 
representative compounds of this class of derivatives is UP101 which showed, as we 
can see from table 6, a high inhibition activity of the ECS enzyme but not selectivity 
towards MAGL.  
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Tab. 6 Inhibition activity of UP101 53. 
 
Other OP derivatives which did not showed high selectivity for MAGL versus FAAH 
are CPO and Paraox reported in figure 34 
62,63,64
:  
 
Fig. 34 CPO and Paraox derivates. 
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An other OP nerve agent that did not demonstrated high selectivity for MAGL is IDFP  
(Isopropyldodecylfluorophosphonate); it is a potent inhibitor of both FAAH and MAGL 
(IC50 values of 3 and 0.8 nM, respectively) but also of many additional serine 
hydrolases, such as the alternate 2-AG hydrolase ABHD6, neuropathy target esterase, 
and the ether-lipid metabolic enzyme KIAA1363. IDFP administrated to mice caused 
dramatic elevations in brain endocannabinoid levels (10-fold), but the side effects seen 
in mice treated with the this compound have been multiple: hypothermia, catalepsy, 
hypomotility as well as death (by a CB1 recptor-independent mechanism) 
51
. 
 
 
 
Fig. 35 IDFP 
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Monoacylglycerol lipase (MAGL) is a membrane-associated cytosolic serine 
hydrolase with the highest expression levels in the brain, white adipose tissue 
and liver. MAGL preferentially hydrolyzes monoacylglycerols to glycerol and 
fatty acid, and its main substrate is represented by the endocannabinoid 2 -
arachidonoylglycerol (2-AG) 
39
. The biosynthetic pathway of 2-AG starts from 
the hydrolysis of membrane phospholipids, mostly PIP2 species, by 
phospholipase C (PLC), resulting in the production of diacylglycerol (DAG), 
which is finally hydrolyzes by diacylglycerol lipase (DAGL) in 2-AG (Fig. 26) 
51
. 
 
Fig. 36 2-AG biosynthesis 51. 
 
2-AG acts primarily by binding to both cannabinoid G protein-coupled 
receptors CB1 and CB2, and it is either synthesized on demand or likely 
associated to binding proteins in spatially separated pools  (Fig. 37) 
51
. 
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Fig. 37 Schematic of retrograde endocannabinoid signaling in the nervous system  51. 
 
Pharmacological inhibition of MAGL activity in vivo leads to a strong 
accumulation of 2-AG, in particular in the brain which triggers a higher 
activation of CB1 and CB2 receptors (in the brain, MAGL is responsible for 
about 80% of the hydrolysis of 2-AG while the remaining 20% arises mainly 
from the activity of other two serine hydrolases, α,β-hydrolase-6 (ABHD-6) and 
-12 (ABHD-12) 
39
. 
Furthermore recent studies have shown that 2-AG is also substrate of 
cyclooxygenase (COX)-2. As a consequence, substrate-selective inhibition of 
COX-2 leads to increased 2-AG levels. According to these findings, it is crucial 
to understand where and under which circumstances each enzyme is responsible 
for controlling 2-AG levels for the developement of new drugs. Another crucial 
element to take in consideration when interfering with 2-AG metabolism is that, 
although 2-AG is a bioactive lipid in its own right, it is also an intermediate in 
the production of several other bioactive lipids.  For instance, MAGL plays a 
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key role in the control of arachidonic acid tissue levels, and thus in the 
production of prostaglandins during inflammation. Furthermore, 2-AG can be 
also channelled through COX-2 and subsequent prostaglandin synthase activity 
leading to the production of prostaglandin glycerol esters (PG-Gs). Altogether 
these elements demonstrate the close relationship between the endocannabinoid 
and eicosanoid system and highlight the key role of the metabolism of 2-AG in 
inflammation-related pathologies. The consequences of MAGL inhibition in 
mouse brain also revealed a cannabinoid-receptor-independent reduction in the 
production of several eicosanoids, with a decrease in proinflammatory cytokine 
production, probably as a result of the decrease in arachidonic acid levels more 
than the increase in 2-AG levels. Therefore, MAGL-mediated hydrolysis of 2-
AG contributes to the arachidonic acid pool in the brain. Increased 
endocannabinoid levels, expecially 2-AG, have been observed in vivo in 
inflammation-related desease, and have been connected to their potential to 
modulate such pathologies. For example, 2-AG levels are enhanced in various 
neuropathologies with an inflammatory component, such as multiple sclerosis, 
Parkinson’s disease or Alzheimer’s disease.                                                      
An interesting therapeutic strategy in a neurological setting could be the 
combining of the known neuroprotective properties of endocannabinoids with 
their anti-inflammatory potential, to reach a simultaneous control of 
neuroinflammation and neurodegeneration 
27,36
.  
Finally, in peripheral tissues often MAGL shows changes in other 
monoacylglycerols, consistent with its lipolytic role as the final step of 
triglyceride hydrolysis. Indeed, MAGL seems to play a key role in the most 
aggressive cancer through controlling global FFAs (free fatty acid) levels that 
serve as the building blocks for synthesis of pro-tumorigenic signaling lipids 
such as PGE2 and lysophosphatidic acid (LPA) 
39
.  
Therefore, inhibitors of 2-AG metabolism may represent an attractive 
therapeutic approach for the treatment of pain, inflammation, anxiety, 
neurodegeneration, cancer and other disorders. 
MAGL is a serine hydrolase belonging to the “α/β hydrolase fold” family, with 
a central β sheet core surrounded by a variable number of α helicals. The 
catalytic triad is formed by Ser
122
, Asp
239
 and His
269
, and in addition there are 3 
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cysteine residues appear to contribute to the
 
regulation of its functions (Fig. 38) 
22,53
. 
 
 
Fig.38 Tertiary structure and schematic diagram of MAGL 65. 
 
Several studies have led to the design and synthesis of compounds able to inhibit 
MAGL catalytic activity. Because of the serine hydrolase nature of MAGL, a large 
group of inhibitors is represented by compound able to bind covalently to the 
nucleophilic serine, such as compounds with a carbamate (JZL184) and a urea 
(SAR629) as functional groups. JZL184 is a piperidine derivate and SAR629 is a 
piperazine derivative with a strong selectivity for MAGL over FAAH, showing a 
similar mechanism of inhibition. In particular, SAR629 mechanism of inhibition 
involves the formation of a relatively stable carbamate adduct with the catalytic serine. 
MAGL–SAR629 co‐structure allows the identification of pharmacophoric points (Fig. 
29): the carbonyl oxygen of the urea function is necessary to create the only polar 
interaction between the inhibitor and the Ser
122
 of the protein. One of the fluorophenyl 
groups probably interacts with some hydrophobic residues and the piperazine group is a 
linker use to orient the other moieties toward pharmacophoric points (carbonyl oxygen 
and aromatic substituent). This linker could be probably replaced by other moieties 
22,65
. 
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Fig. 39 SAR629 pharmacophoric points 50. 
Another class of MAGL inhibitors are compounds inspired by the endogenous substrate 
2‐AG 22,51,53  which are characterized by: a fatty acid chain (hydrophobic fragment), a 
linker and a polar substituent (Fig. 40): 
 
Fig. 40 2-AG inhibitors moieties. 
These compounds contain the arachidonic acid chain in their structure and this moiety 
could be oxidized in biological tissue, limiting the selectivity of the compounds. 
Moreover the arachidonic acid plays a key role as a metabolite in several pathways and 
therefore can be recognized by different enzymes, including lipases and 
cyclooxygenases. For this reason the arachidonic acid structure was substituted by a 
bioisostere group such as biphenyl group 
65
. In particular, compounds with general 
structure A reported in Fig. 41 demonstrated to be potent inhibitors of human 
recombinant MAGL 
66
. 
linker 
hydrophobic 
portion 
polar pharmacophore 
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Fig. 41 MAGL inhibitors. 
 
In the laboratory were I performed my thesis work, a series of compounds with general 
structure B (Fig. 42) was previously developed. In these compounds, derived from the 
general structure of Fig. 41, biphenyl moiety was replaced by a phenyl-piperazine 
moiety, according to the linker’s structure of previously developed MAGL inhibitors.  
 
Fig. 42 Compounds with general structure B 
 
These compounds present all the features typical of MAGL inhibitors: the hydrophobic 
portion is represented by a phenyl-piperazine moiety; the polar pharmacophore is 
represented by urea, thiourea, or amide functionality; the spacer is characterized by a 
three-carbon atom chain. These compounds were then tested at a 5 µM of final 
concentration and the percentages of MAGL inhibition of these derivatives are reported 
in Tab.7: 
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Tab.7 MAGL inhibitory activity of compounds with general structure B tested at 5 µM. 
 
The results obtained showed that all compounds present good MAGL inhibitory activity 
and the most potent inhibitor of these series is the amide derivative B4, which inhibits 
enzyme activity by 80.6%. 
During the first part of my thesis work I synthesized compound 1 (Figure 43), the 
carbamic analogue of compound B4, since it is well known that carbamate derivatives 
constitute a good template for inhibiting serine hydrolases. 
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Fig.43 Compound 1. 
The carbamate moiety was insert accordingly to the established mechanism of covalent 
binding of this function to the nucleophilic serine, such as other inhibitors like JZL184 
(Fig. 42) 
57
:       
                                       Fig. 44 Mechanism of covalent inactivation of MAGL by JZL184 57. 
This derivate was prepared as showed in Scheme 1: 
 
Scheme 1 
Reagents and conditions: (i) Et3N, ACN, 16 h, 85 °C; (ii) EtOH, NH2NH2, 5 h, 105 °C; (iii) 
Pyridine, THF, Phenyl Chloroformate, 24 h, r.t. 
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The commercial available 1-phenylpiperazine reacted and 2-(3-
bromopropyl)isoindoline-1,3-dione were refluxed in acetonitrile to give compound 14, 
which was then subjected to hydrolisis to give the amine 15 through a reaction with 
NH2NH2 in EtOH at 105 °C. The obtained primary amine 15 was treated with 
commercial phenyl chloroformate, in presence of pyridine, to give the carbamate 
derivative 1, which was purified by silica gel flash chromatography. 
After, to further study the structure-activity relationships of this class of compounds, the 
efforts were focused on the modification of the primary scaffold B. The phenyl amide 
functionality was chosen as polar pharmacophore for the entire novel developed 
compounds, since the amide derivative B4 gave the best results in the previous series 
(Tab. 7). Therefore, the hydrophobic region of compound B4 was ampliated trying to 
encrease Wan der Walls interactions with hydrophobic residues, by inserting a 
substituent in para position to the piperazine ring. Moreover, other structural changes in 
carbon atom chain were made in order to evaluate which is the best distance between 
the two moieties (polar group and hydrophobic fragment) to obtain the best shaping in 
the natural binding pocket of MAGL. Thus the polar pharmacophore (the amide 
functionality) was directly linked to the hydrophobic moiety rather than inserting a 
spacer. 
 
Fig. 45 Modification of structure of compound B4. 
 
My thesis work was inserted in this research project and provided the synthesis of 
compounds 2-5 (Figure 46). 
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Fig. 46 Compounds 2-5. 
 
Compounds 2-4 were preparated following the synthetic route showed in Scheme 2.  
The commercial available 1-phenylpiperazine was treated with commercial benzoyl 
chloride, in presence of anydrous CH2Cl2 and Et3N to give the compound 2. After, 1-
phenylpiperazine reacted with commercial di-tert-butyl dicarbonate to give derivative 
16, which was treated with N-bromosuccinnimide (NBS) to obtain the Boc derivative 
17; from compound 17, through a deprotection with 37% HCl, was obtained compound 
18, which was converted in amide 3 by reacting with benzoyl chloride in a way similar 
to that previously used for compound 2. Starting from protected brominated compound 
17, through a Suzuki cross-coupling reaction with thiophen-2-yl boronic acid, in 
presence of tetrakis (triphenylphosphine)palladium(0) as catalyst and aqueous sodium 
carbonate as base, in dry 1,4-dioxane, at 100 °C, was converted in compound 19. 
Compound 19 was deprotected with 37% HCl to afford compound 20, which was 
treated with benzoyl chloride to give the compound 4.  
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Scheme 2 
Reagents and conditions: (i) benzoyl chloride, anydrous CH2Cl2, Et3N,4h, r.t.; (ii) di-tert-butyl 
dicarbonate, DMAP, anydrous CH2Cl2, 2h, r.t.; (iii) NBS, DMF, overnight, r.t.; (iv) 37% HCl, 
AcOEt, 1h, r.t.;(v) benzoyl chloride, anydrous CH2Cl2, Et3N,4h, r.t.; (vi) thiophen-2-yl boronic 
acid, tetrakis, Na2CO3,water, dioxane, overnight, 100 °C; (vii) 37% HCl, AcOEt, 1h, r.t.; (viii) 
benzoyl chloride, anydrous CH2Cl2, Et3N,4h, r.t. 
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Compound 5 was preparated through the synthetic pathway depicted in Scheme 3. 
 
Scheme 3 
Reagents and conditions: (i) ACN, Et3N,16h, 85 °C; (ii) NH2NH2 monohydrate, EtOH, 5h, 105 
°C; (iii) benzoyl chloride, anydrous CH2Cl2, Et3N, 4h, r.t. 
 
Amine 22 was obtained following a two step procedure similar to that previously used 
for analogue compounds. Thus, the synthetized phenylpiperazine derivative 20 was 
reacted with N-(3-bromopropyl)phthalimide and triethylamine to give 2-(3-(4-(4-
bromophenyl)piperazin-1-yl)propyl)isoindoline-1,3-dione 21, which was treated with 
hydrazine monohydrate in EtOH, at 105 °C to cleave N-alkylated phtalimide affording 
the primary amine 22; then this compound was treated with benzoyl chloride and 
trimethylamine in anhydrous dichloromethane to give the amide 5. 
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Recently, a novel class of MAGL inhibitors was reported in a patent 
(WO2010124121A1)
67 
developed by Kristen M. and co-workers. These compounds 
present general structure C (Figure 47), in which the phenylpiperazine moiety is 
replaced by a pyrimidinepiperazine moiety, and the most of these derivatives showed 
interesting inhibitory capacity, on the order of low micromolar/ nanomolar range and 
the most active inhibitor C1 showed to inhibit MAGL through a reversible 
mechanism
67,68
. 
 
Fig. 47 Compound with general structure C and compound C1 
67. 
 
The crystal structure of MAGL in complex with this reversible and pharmacologically 
relevant ligand C1 has been solved to 1.35 Å by Schalk-Hihi and co-workers 
68
. This 
work has represented the first example of crystallization of MAGL with a reversible 
inhibitor.
 
As it is shown in Figures 48 and 49, compound C1 is bound in an extended and closed 
binding pocket, which is located between helices α4, α6, α7, and α5 (Fig. 48). The 
amide carbonyl of the compound points into the oxyanion hole (the structurally 
conserved network of hydrogen-bond donors, which comprises Gly
50
, Ala
51
, Met
123
, 
Gly
124
 and helps to stabilize the anionic transition state of the catalytic reaction) and 
forms an important hydrogen bond with the amide nitrogen of Met
123
 near to the 
catalytic serine. The azetidine-piperazine-pyrimidine part of the ligand projects into a 
narrow amphiphilic pocket and fills the available space almost completely. This portion 
of the ligand does not partecipate in hydrogen bond interactions with the protein, but 
one of the pyrimidine nitrogens forms a hydrogen bond to a water-network involving 
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two buried water molecules and the side-chains of residues Glu
53
, Arg
57
, and His
272
. A 
face-to-face π-π stacking interaction of the pyrimidine ring with Tyr194 provides further 
interaction energy (Fig.49). 
 
 
Fig.48 Position of the compound in the binding site 68. 
 
The benzoxazole portion of the ligand is located in a hydrophobic environment 
constituted from side chains of aliphatic residues. The cyclohexane portion of the ligand 
form mostly van der Waals interactions with the protein (Fig. 49). 
 
Fig. 49 Interactions between the compound and aminoacid residues 68. 
Furthermore, the same research group has shown the comparison between the binding 
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mode of a non-covalent (compound C1) and a covalent (SAR629, for structure see Fig. 
39) inhibitors. As it is depicted in Fig. 50, compound C1 (teal colored carbons) spans 
the entire active site cavity of MAGL (cyan), whereas SAR629 (orange carbons), which 
is covalently bound to the hydroxyl group of Ser
122, solely occupies the ‘‘left’’ section 
of the binding cavity (yellow). Moreover they have demonstrated that these two 
compounds interact with two different conformation of MAGL, since SAR629, 
differently from compound C1, is unable to bind in MAGL close conformation. 
Therefore, this work also offers guidance for efforts to develop inhibitors of MAGL 
with a reversible behaviour, since it is well known that the use of irreversible MAGL 
inhibitors determined an unwanted chronic MAGL inactivation which acquires an 
antagonism function of the endocannabinoid system, whereas reversible MAGL 
inhibitors could partially inhibit the enzyme, leaving the endocannabinoid system intact. 
 
Fig. 50 Comparison between the binding mode of the non-covalent inhibitor C1 (teal carbon atoms) and the 
covalent inhibitor SAR629 (orange carbon atoms) 68. 
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Starting from these studies, during the second part of my thesis work, I focused the 
attention on the design and synthesis of a novel class of potential MAGL inhibitor with 
general structure D (Fig. 51). These compounds are characterized by a piperazine-
pirimidine portion and an amide group as polar pharmacophore. The amide group was 
preserved because it seems to be the best polar moiety for reversible MAGL inhibition, 
and it was directly linked or separated by a spacer consisted of two- or three-carbon 
atoms chain from the pyrimidinepiperazine moiety. Compounds with no carbon atom 
chain were prepared to evaluate the relevance of the presence of a distance spacer. 
Compounds with two- and three carbon atoms chain were synthetized to mimic the 
azetidine moiety reported in the aforementioned patent, and to understand the 
importance of a rigid/flexible structure. Moreover, these compound were prepared also 
according to the results obtained by compounds of series B, especially amide B4. 
 
Fig. 51 Compounds with general structure D. 
 
Moreover, three different classes of amide derivatives were prepared: 
1) phenyl amide derivatives, which gave the best results with the previous series 
(B); 
2) biphenyl amide derivatives, to evaluate the effect of an increase of the 
hydrophobicity; 
3) the amides derived from (RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid 
(ibuprofen), since it was recently emerged that the association of a non steroidal 
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anti-inflammatory drug (NSAID) with a compound inhibiting endocannabinoid 
degradation could be synergistic in the resolution of pathologies with an 
inflammatory component and open up new therapeutic path for a multitarget 
approach 
36
.  
Derivates without any spacer, compounds 6-8, were prepared following the synthetic 
pathway showed in Scheme 4. 
 
Scheme 4 
Reagents and conditions: (i) benzoyl chloride, anydrous CH2Cl2, Et3N, 4h, r.t.; (ii) [1,1’- 
biphenyl]- 4-carbonyl chloride, anydrous CH2Cl2, Et3N, 4h, r.t.; (iii) 2-(4-isobutylphenyl) 
propanoyl chloride, anydrous CH2Cl2, Et3N, 4h, r.t. 
 
The commercial available 2-(piperazin-1-yl)pyrimidine was used as starting material for 
the synthesis of the three derivates; first it was treated with commercial benzoyl 
chloride, in presence of anydrous CH2Cl2 and Et3N to give the compound 6. 2-
(piperazin-1-yl)pyrimidine reacted with the synthetized [1,1’- biphenyl]- 4-carbonyl 
chloride (Scheme 5) to obtain the derivate 7. Finally the starting material was treated 
with the synthetized derivate (+)-2-(4-isobutylphenyl) propanoyl chloride (Scheme 5), 
in the same conditions of the others reactions, to afford the compound 8. All these 
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compounds were purified by flash column chromathography on silica gel. 
 
The synthesis of acid chlorides ([1,1’- biphenyl]- 4-carbonyl chloride and (+)-2-(4-
isobutylphenyl) propanoyl chloride)  is illustrated in scheme 5. 
 
Scheme 5 
Reagents and conditions: (i) SOCl2, 3h, 85 °C; (ii) SOCl2, 3h, 85 °C. 
 
The commercial available [1,1’- biphenyl]- 4-carboxylic acid and (+)-2-(4-
isobutylphenyl) propanoic acid were refluxed with SOCl2 to give the corresponding acid 
chlorides [1,1’- biphenyl]- 4-carbonyl chloride  and (+)-2-(4-isobutylphenyl) propanoyl 
chloride respectively. 
Derivates whith two-carbon atoms chain as spacer, compounds, 9-11 were prepared as 
showed in Scheme 6. 
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Scheme 6 
 
Reagents and conditions:(i) ACN, Et3N,16h, 85 °C; (ii) NH2NH2, EtOH, 5h, 105 °C; (iii) 
benzoyl chloride, anydrous CH2Cl2, Et3N,4h, r.t.;(iv) [1,1’- biphenyl]- 4-carbonyl chloride, 
anydrous CH2Cl2, Et3N,4h, r.t.;(v) (+)-2-(4-isobutylphenyl) propanoyl chloride, anydrous 
CH2Cl2, Et3N,4h, r.t. 
 
The commercial 2-(piperazin-1-yl)pyrimidine reacted with N-(2-
bromoethyl)phthalimide and triethylamine to give compound 23, which was treated 
with hydrazine monohydrate in EtOH, at 105 °C to cleave N-alkylated phtalimide 
affording the primary amine 24. Compound 24 was used as starting material to obtain 
compounds 9, 10 and 11. First the amine was treated with commercial benzoyl chloride 
to afford compound 9. The starting material reacts with [1,1’- biphenyl]- 4-carbonyl 
chloride, in presence of anydrous CH2Cl2 and Et3N, to afford derivate 10. Compound 24 
was finally treated with (+)-2-(4-isobutylphenyl) propanoyl chloride to give compound 
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11. 
During my thesis work several attempts (Scheme 7) were made for the preparation of 
the primary amine 24, the key compound for the synthesis of compounds 9-11 (Scheme 
6). Preparation of derivative 24 was previously planned as reported in Scheme 7. 
 
Scheme 7 
 
The first step of the preparation of the amine provided the treatment of 2-(piperazin-1-
yl)pyrimidine  with 2-chloroacetonitrile, in presence of K2CO3 and toluene, at 102 °C 
for 3 hours to give the intermediate 25. This compound was treated with: 
 H2/Pd in presence of MeOH for 12 h at r.t.; 
 LiAlH4 in presence of anydrous THF for 1 h at r.t. 
Both these attempts gave unsatisfying results, unlike was reported in literature. 
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Derivates with a three-carbon atoms chain as spacer, 12-14, were prepared as showed in 
scheme 8. 
 
Scheme 8 
Reagents and conditions: (i) ACN, Et3N, 16h, 85 °C; (ii) NH2NH2, EtOH, 5h, 105 °C; (iii) 
benzoyl chloride, anydrous CH2Cl2, Et3N, 4h, r.t.;(iv) [1,1’- biphenyl]- 4-carbonyl chloride, 
anydrous CH2Cl2, Et3N, 4h, r.t.;(v) (+)-2-(4-isobutylphenyl) propanoyl chloride, anydrous 
CH2Cl2, Et3N, 4h, r.t. 
 
The commercial 2-(piperazin-1-yl)pyrimidine was treated with N-(3-
bromopropyl)phtalimide and Et3N, in ACN at 85 °C to give compound 26, which was 
then hydrolized with hydrazine monohydrate to obtain compound 27. The primary 
amine was reacted with benzoyl chloride to give compound 12. Compound 27 was 
treated with [1,1’- biphenyl]- 4-carbonyl chloride, in presence of anydrous CH2Cl2 and 
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Et3N, to afford the derivate 13. The amine 27 was finally treated with (+)-2-(4-
isobutylphenyl)propanoyl chloride, in the same conditions, to obtain compound 14.
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6.Equipments and methods 
 
Structure of synthesized compound was verified by 
1
H NMR analysis. NMR spectra 
were obtained with a Bruker 400MHz spectrometer. Chemical shift (δ) are reported in 
parts per million (ppm) downfield from tetramethylsilane and referenced to the solvent 
residual peak. Coupling constants (J) are reported in Hertz (Hz). Evaporation was 
performed in vacuo by a rotating evaporator. All reactions was monitored by thin-layer 
chromatography (TLC) using Merck aluminium silica gel (60 F254) sheets that were 
visualized under a UV lamp (λ = 254 nm). Silica gel flash chromatography was 
performed using silica gel (Kieselgel 40, 0.040-0.063 mm; Merck).  
Chemistry: commercially available reagents were purchased from Sigma Aldrich or 
Alfa Aesar, and used without purification.  
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2-[ 3-( 4- phenylpiperazin-1-yl) propyl]- 1H- isoindole- 
1,3(2H)- dione. (14) 
 
To a solution of 1.34 g of the commercial available N-(3- bromopropyl)phtalimide (5.00 
mmol) in 25 mL of ACN was added a mixture of 1.40 mL of TEA (10.00 mmol) and 
0.76 mL of phenylpiperazine (5.00 mmol). The reaction was heated under reflux at 105 
°C for 16 hours. Then the reaction mixture was cooled, water was added and the product 
was extracted with CH2Cl2. The organic phase was dried over anhydrous Na2SO4, 
filtered and after that the solvent was evaporated under reduce pressure to obtain 14  
(1.083 g, 3.1 mmol) as a yellow solid sufficiently pure for succeeding reactions. 
 
Yield: 62% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.82-7.86 (m, 2H, Ar); 7.67-7.71 (m, 2H, Ar); 7.20-7.26 
(m, 2H, Ar); 6.80-6.88 (m, 3H, Ar); 3.77-3.84 (t, J=13.89 Hz, 2H, CH2); 3.03-3.07 (m, 
4H, H piperazine); 2.45-2.57 (m, 6H, H piperazine, CH2); 1.85-1.98 (m, 2H, CH2). 
 
 
 
 
 
 
 
 
 
 
 
 Experimental part 
85 
3-(4- phenylpiperazin- 1-yl)propan- 1- amine (15). 
 
2,0 g of 14 (5.73 mmol) were solubilized in 40 mL of EtOH under stirring; to this 
solution 5.3 mL of NH2NH2  monohydrate (17,19 mmol) were added and the mixture 
was heated under reflux at 78 °C for 5 hours. When the reaction mixture was cooled, it 
was alkalized with 5% NaOH until pH = 8. After the evaporation of the solvent under 
reduced pression, the product was extracted with CH2Cl2 and washed with water. The 
organic layer was dried over anhydrous Na2SO4, filtered and evaporated. The residue 
obtained was crystallized with high-boiling point petroleum ether to obtain 15 (1.105 g, 
5.04 mmol) as a yellow solid. 
 
Yield: 88% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.26-7.22 (m, 2H, Ar); 6.93-6.82 (m, 3H, Ar); 3.21-3.12 
(m, 4H, H piperazine); 2.79-2.43 (m, 8H, H piperazine, 2 CH2); 2.03 (bs, 2H, NH2); 
1.72-1.65 (m, 2H, CH2). 
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Phenyl [3-(4- phenylpiperazin- 1-yl) propyl] carbamate 
(1) 
 
300 mg of 15 (0.86 mmol) were solubilized in 3.4 mL of dry THF. After, to the reaction 
mixture 75 µL of pyridine (0.95 mmol) were added under stirring. The solution was 
cooled to 0 °C and then 0.1 mL of phenyl chloroformate (0.95 mmol) were added 
dropwise. The reaction was heated to room temperature and stirred for 24 h. Then the 
mixture was diluted with EtOAc and washed with water. The organic phase was dried 
over anhydrous Na2SO4, filtered and concentrated under vacuum to afford a crude 
residue that was purified by silica gel flash chromatography, using petroleum ether (b,p, 
= 40-60 °C)/EtOAc 3: 8 as eluent, to give the pure compound 1 ( 295 mg, 0.77 mmol) 
as a yellow solid. 
 
Yield: 90% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.82-7.85 (m, 2H, Ar); 7.67-7.72 (m, 2H, Ar); 7.21-7.26 
(m, 2H, Ar); 6.84-6.88 (m, 3H, Ar); 3.78-3.82 (t, J=13.85  Hz, 2H, CH2); 3.06-3.08 (m, 
4H, piperazine); 2.49-2.57 (m, 6H, H piperazine, 2CH2); 1.89-1.96 (m, 2H, CH2). 
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Phenyl (4-phenyl piperazin-1-yl) methanone (2) 
 
A solution of 0.3 mL of phenylpiperazine (2.00 mmol) and 0.4 mL of Et3N (3.00 mmol) 
in CH2Cl2 (5 mL) was cooled to 0 °C and after, 0.2 mL of benzoyl chloride (2.00 mmol) 
were added dropwise. The mixture was heated to room temperature and left under 
stirring for 1 h. Then the product was diluted with CH2Cl2 and washed with water. The 
organic layer was dried over anhydrous Na2SO4, filtered and the solvent evaporated 
under reduced pression, to obtain 2 (500 mg, 1.96 mmol) as a yellow oil. 
 
Yield: 98% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.43-7.44 (m, 5H, Ar); 7.26-7.31 (m, 2H, Ar); 6.89-6.95 
(m, 3H, Ar); 3.60-3.94 (m, 4H, piperazine); 3.08-3.26 (m, 4H, piperazine). 
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Tert- butyl 4- phenylpiperazine- 1- carboxylate (16) 
 
408 mg of di-tert-butyl dicarbonate (2.00 mmol) were added in small portions, at 0 °C 
to a mixture of 0.3 mL of phenylpiperazine (2.00 mmol), 0.8 mL of Et3N (6.00 mmol), 
7 mg of DMAP (0.06 mmol) and 9.2 mL of anydrous CH2Cl2. Few minutes after the 
addiction, the solution was heated to room temperature and left under stirring for 2 h. 
Then reaction was quenched with water and extracted with CH2Cl2. The organic phase 
was washed with brine, dried over anhydrous Na2SO4, filtered and evaporated to 
dryness to obtain 16 (346 mg, 1.32 mmol) as a yellow solid. 
 
Yield: 66% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.25-7.30 (m, 3H, Ar); 6.91-6.94 (m, 2H, Ar); 3.57-3.59 
(m, 4H, piperazine); 3.12-3.14 (m, 4H, piperazine); 1.48 (s, 9H, 3CH3). 
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Tert- butyl 4- (4- bromophenyl) piperazine- 1- 
carboxylate (17) 
 
340 mg of 16 (1.3mmol) were dissolved in 1.2 mL of anhydrous DMF. To this solution 
a mixture of 239 mg of NBS (1.34 mmol) and 1.1 mL of anhydrous DMF were added. 
The reaction mixture was stirred at room temperature overnight. Then water was added 
leading to the formation of a precipitate that was filtered under reduced pressure. The 
residue was dissolved in CH2Cl2 and washed with brine. The organic layer was dried 
over anhydrous Na2SO4, filtered and the solvent was evaporated under reduced pressure 
to obtain 17 (267 mg, 0.78 mmol) a light yellow solid. 
 
Yield: 60% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.35-7.37 (m, 2H, Ar); 6.81-6.83 (m, 2H, Ar); 3.57-3.59 
(m, 4H, piperazine); 3.09-3.12 (m, 4H, piperazine); 1.48 (s, 9H, 3CH3). 
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Tert- butil 4- [4-(thiophen-2-yl) phenyl] piperazine- 1- 
carboxylate (19) 
 
The cross-coupling reaction was performed in a vial under N2 atmosphere. The vial was 
charged with 267 mg of 17 (0,78 mmol), 166 mg of solid Na2CO3 (1.56 mmol), 164 mg 
of thiophen-2-yl boronic acid (1.17 mmol), 45 mg of tetrakis (0.04 mmol), 2.9 mL of 
water and 8.8 mL of anhydrous 1,4-dioxane. The mixture was heated at 100 °C 
overnight. Then the reaction mixture was cooled, partitioned between EtOAc and water, 
and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered 
and the solvent was evaporated under reduced pression. The crude residue was purified 
by silica gel flash chromatografy, using toluene/EtOAc 7:3 as eluent, to give the pure 
compound 19 (108 mg, 0.31 mmol) as an orange solid. 
 
Yield: 49% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.51-7.53 (m, 2H, Ar); 7.18-7.20 (m, 2H, thiophene); 7.03-
7.05 (m, 1H, thiophene); 6.94-6.95 (m, 2H, Ar); 3.57-3.61 (m, 4H, piperazine); 3.18-
3.19 (m, 4H, piperazine) 1.49 (s, 9H, 3CH3). 
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1-[4-(thiophen-2-yl)phenyl] piperazine (20) 
 
600 mg of 19 (1.74 mmol) was added to a solution of 5.7 mL of 37% HCl (69.67 mmol) 
and 29.1 mL of EtOAc. The mixture was stirred for 1 h at room temperature. Then the 
solvent was evaporated and the mixture was partitioned between EtOAc and water. 
After the separation, the aqueous layer was alkalinized with saturated Na2CO3 until 
pH=7. An insoluble precipitate was formed and the residue was solubilized with CH2Cl2 
and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered 
and the solvent was evaporated under reduced pression to obtain 20 (394 mg, 2.14 
mmol) as a yellow solid. 
 
Yield: 66% 
 
1
H-NMR: (DMSO) δ (ppm) 7.49-7.51 (m, 2H, thiphene); 7.29-7.35 (m, 2H, Ar); 7.06-
7.09 (m, 1H, thiophene); 6.96-6.98 (m, 2H, Ar); 4.15 (bs, 1H, NH2); 3.04-3.051 (m, 4H, 
piperazine); 2.84-2.87 (m, 4H, piperazine). 
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Phenyl [4-(4-( thiophen-2-yl)phenyl) piperazin-1-
yl]methanone (4) 
 
200 mg of 20 (0.82 mmol) and 0.2 mL of Et3N (1.23 mmol) were solubilized in 2 mL of 
CH2Cl2. The solution was cooled to 0 °C and added of 90 µL (0.82 mmol) of benzoyl 
chloride were added dropwise and the reaction was heated to room temperature and 
stirred for 4 h. Then the mixture was diluted with CH2Cl2 and washed with water. The 
organic phase was dried over anhydrous Na2SO4, filtered and the solvent evaporated to 
dryness, to obtain 4 (117 mg, 0.32 mmol) as an orange solid. 
 
Yield: 40% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.52-7.54 (m, 2H, Ar); 7.43-7.44 (m, 5H, Ar); 7.20-7.21 
(m, 2H, Ar); 7.04-7.06 (m, 1H, thiophene); 6.94-6.96 (m, 2H, thiophene); 3.89-4.08 (m, 
2H, piperazine); 3.59-3.71 (m, 2H, piperazine); 3.12-3.51 (m, 4H, piperazine). 
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1-(4-bromophenyl)piperazine (18) 
 
To a solution of compound 17 (1.00 g, 2.93 mmol) in EtOAc (49 mL), HCl (37 %, 9.6 
mL, 117.2 mmol) was added and the resulting mixture was left under stirring at room 
temperature for 1 hour. Then the solution was partitioned between CH2Cl2 and water, 
and the aqueous layer was neutralized with saturated NaHCO3, until a white precipitate 
was observed and then extracted several times with CH2Cl2. The organic phase was then 
dried over anhydrous Na2SO4, filtered and concentrated under vacuo to give light 
yellow solid, corresponding to compound 18 (868 mg, 3.6 mmol), which was used for 
the following step without further purification. 
 
Yield: 90% 
 
1
H-NMR: (CDCl3) δ  (ppm) 7.27-7.31 (m, 2H, Ar); 6.53-6.28 (m, 2H, Ar); 3.48-3.59 
(m, 4H, Ar); 2.84-2.93 (m, 2H, Ar); 1.16 (bs, 1H, NH). 
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[4-(4-bromophenyl)piperazin-1-yl](phenyl) methanone 
(3) 
 
To a solution of 18 (200 mg, 0.83 mmol), Et3N (0.2 mL, 1.24 mmol) and CH2Cl2 (2.1 
mL) at 0 °C, benzoyl chloride (83 µL, 0.83 mmol) was added dropwise. The solution 
was heated to room temperature and left under stirring for 4 h. Then the mixture was 
diluted with water and extracted several times with CH2Cl2; the organic layer was dried 
over anydrous Na2SO4, filtered and evaporated under reduced pression to obtain pure 3 
as a yellow solid (182 mg, 0.55 mmol). 
 
Yield: 66% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.43-7.44 (m, 4H, Ar); 7.34-7.38 (m, 2H, Ar); 7.26-7.27 
(m, 1H, Ar); 6.78-6.81 (m, 2H, Ar); 3.56-3.95 (m, 4H, piperazine); 3.09-3.24 (m, 4H, 
piperazine). 
 
 
 
 
 
 
 
 
 
 Experimental part 
95 
2-[3-(4-(4-bromophenyl)piperazin-1-yl)propyl]- 
isoindoline-1,3-dione (21) 
 
556 mg of N-(3-bromopropyl)phtalimide (2.07 mmol) were solubilized in 10.4 mL of 
ACN under stirring. To this solution Et3N (0.6 mL, 4.15 mmol) followed by 20 (500 
mg, 2.07 mmol) were added. The reaction mixture was refluxed at 85 °C, under stirring 
for 16 h. Then the solution was diluted with CH2Cl2 and washed with water. The 
organic phase was dried over anhydrous Na2SO4, filtered and the solvent was 
evaporated under reduced pression to give compound 21 (1.035 g, 2.41 mmol) as a 
yellow solid, which was used in the following step without further purification. 
 
Yield: 63% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.81-7.84 (m, 2H, Ar); 7.68-7.72 (m, 2H, Ar); 7.31-7.32 
(m, 2H, Ar); 6.70-6.73 (m, 2H, Ar); 3.78-3.81 (t, 2H, CH2, J=13.7 Hz); 3.05-3.86 (m, 
3H, piperazine); 2.53-2.58 (m, 4H, 2H piperazine, CH2); 2.17-2.19 (m, 3H, piperazine); 
1.94-1.98 (m, 2H, CH2).  
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3-[4-(4- bromophenyl) piperazin-1-yl] propan-1-amine 
(22) 
 
To a solution of compound 21 (1.1 g, 2.41 mmol) in EtOH (16.8 mL) were added 0.4 
mL of NH2NH2 monohydrate (7.23 mmol) under stirring and the solution was heated 
under reflux at 105 °C for 5h. Then the reaction mixture was cooled and alkalized with 
5% NaOH until pH=8 and the solvent evaporated under vacuum. The residue was 
diluted with CH2Cl2 and washed with water. The organic layer was dried over 
anhydrous Na2SO4, filtered and the solvent evaporated under reduced pression to give a 
yellow oil, which was crystallized with high-boiling point petroleum ether to obtain 22 
(604 mg, 2.02 mmol) as a yellow solid. 
 
Yield: 84% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.31-7.35 (m, 2H, Ar); 6.76-6.79 (m, 2H, Ar); 3.09-3.174 
(m, 4H, piperazine); 2.80-2.83 (m, 2H, CH2); 2.59-2.61 (m, 4H, piperazine), 2.46-2.47 
(t, 2H, CH2, J=14.3 Hz); 1.94 (bs, 2H, NH2); 1.67-1.74 (m, 2H, CH2). 
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N-[3-(4-(4-bromophenyl)piperazin-1-yl)propyl]- 
benzamide (5) 
 
100 mg of 22 (0.33 mmol) and 0.1 mL of Et3N (0.50 mmol) were dissolved in 0.8 mL 
of CH2Cl2; to this solution 35 µL of benzoyl chloride (0.03 mmol) were added dropwise 
at 0°C and, after heating to room temperature, the reaction mixture was left under 
stirring for 4h. Then, the mixture was partitioned between water and CH2Cl2 and 
extracted with CH2Cl2. The organic layer was dried over anydrous Na2SO4, filtered and 
evaporated under reduced pression to give the pure compound 5 (176 mg, 0.44 mmol) 
as a brune solid. 
 
Yield: 66% 
 
1
H-NMR: (CDCl3) δ (ppm) 7.88-7.93 (m, 2H, Ar); 7.30-7.57 (m, 5H, Ar); 6.75-6.80 
(m, 2H, Ar); 3.58-3.62 (m, 2H, CH2); 3.28-3.31 (m, 4H, piperazine); 2.83-2.92 (m, 6H, 
2H CH2, 4H piperazine); 1.98-2.04 (m, 2H, CH2). 
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Phenyl [4-(pyrimidin-2-yl) piperazin-1-yl] methanone (6) 
 
1-(2-pyrimidyl)piperazine (0.2 mL, 1.83 mmol) and Et3N (0.4 mL, 2.74 mmol) were 
dissolved in CH2Cl2 (4.6 mL) and the mixture was cooled at 0 °C. To the reaction 
mixture 0.2 mL of benzoyl chloride (1.83 mmol) were added dropwise. After heating to 
room temperature, the solution was left under stirring for 4 h. Then the crude residue 
was diluted with CH2Cl2 and washed with water. The organic phase was dried over 
anhydrous Na2SO4, filtered and evaporated under vacuum to give the pure compound 6 
(385 mg, 3.25 mmol) as a white solid. 
 
Yield: 89% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.32-8.33 (d, 2H, pyrimidine, J= 4.76 Hz); 7.44-7.72 (m, 
5H, Ar); 6.53-6.56 (t, 1H, pyrimidine, J= 9.52 Hz); 3.79-3.91 (m, 8H, piperazine). 
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[1,1’ biphenyl]-4-yl(4-(pyrimidin-2-yl)piperazin-1-yl) 
methanone (7) 
 
[1,1’- biphenyl]-4-carboxylic acid (150 mg, 0.76 mmol) was refluxed with SOCl2 (0.8 
mL, 11.1 mmol) at 85 °C for 3 h. After the excess of SOCl2 was evaporated under 
nitrogen atmosphere to afford [1,1’- biphenyl]-4-carbonyl chloride, which was directly 
used for the subsequent step. Then it was dissolved in anhydrous CH2Cl2 (0.8 mL), 
cooled to 0 °C and added of a solution of 1-(2-pyrimidil)piperazine (0.1 mL, 0.90 
mmol) and Et3N (0.2 mL, 1.82 mmol) in anhydrous CH2Cl2 (0.8 mL). The mixture was 
left under stirring for 4 h after heating to room temperature. After, to the solution 5 mL 
of 6N HCl were added and the two phases were separated. The organic layer was 
washed with water and brine, dried over anhydrous Na2SO4, filtered and the solvent was 
evaporated to give a crude yellow oil, which was purificated by trituration with 
diethylether to give 7 (104.7 mg, 0.30 mmol) as a yellow solid. 
 
Yield: 40% 
 
1
H-NMR: (DMSO) δ (ppm) 8.44-8.45 (d, 2H, pyrimidine, J= 4.8 Hz); 7.75-7.81 (m, 
4H, Ar); 7.52-7.60 (m, 4H, Ar); 7.43-7.47 (m, 1H, Ar); 6.18-6.74 (t, 1H, pyrimidine, J= 
9.2 Hz); 3.84-3.86 (m, 4H, piperazine); 3.64-3.71 (m, 4H, piperazine). 
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(+)-2-(4-isobutylphenyl)-1-[4-(pyrimidin-2-yl)piperazin-
1-yl] propan-1-one (8) 
 
(171 mg, 0.76 mmol) of (+)-2-(4-isobutylphenyl)propanoic acid was refluxed with 
SOCl2 (0.18 mL, 2.5 mmol) at 85 °C for 3 h. After the excess of SOCl2 was evaporated 
under nitrogen atmosphere to afford (+)-2-(4-isobutylphenyl)propanoyl chloride, which 
was directly used for the subsequent step. Then it was dissolved in anhydrous CH2Cl2 
(0.8 mL), cooled to 0 °C, and added of a solution of 1-(2-pyrimidyl)piperazine (0.2 mL, 
0.91 mmol) and Et3N (0.2 mL, 1.82 mmol) in anhydrous CH2Cl2 (0.9 mL), and after 
cooling to room temperature, the reaction was left under stirring for 4 h. Then the 
reaction mixture was diluted with CH2Cl2 and washed with water and brine. The 
organic phase was dried over anhydrous Na2SO4, filtered and evaporated under reduced 
pressure to give a crude. The residue was purificated by silica gel flash chromatography, 
using ethyl acetate/petroleum ether 1:1 as eluent, to obtain pure 8 (184 mg, 0.52 mmol) 
as a light pink solid. 
 
Yield: 57% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.28-8.29 (d, 2H, pyrimidine, J= 4.8 Hz); 7.15-7.17 (m, 2H, 
Ar); 7.07-7.09 (m, 2H, Ar); 6.49-6.51 (t, 1H, pyrimidine, J= 9.6 Hz); 3.79- 3.88 (m, 4H, 
3H piperazine, 1H CH); 3.39-3.58 (m, 4H, piperazine); 3.06-3.12 (m, 1H, piperazine); 
2.42-2.44 (d, 2H, CH2, J= 7.2 Hz); 1.78-1.88 (m, 1H, CH); 1.45-1.47 (d, 3H, CH3, J= 
6.8 Hz); 0.86-0.88 (d, 6H, 2CH3, J= 6.6 Hz). 
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2-[2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethyl]isoindoline-
1,3-dione (23) 
 
To a solution of 465 mg of N-(2-bromoethyl)phtalimide (1.83 mmol) in 9.2 mL of 
ACN, a mixture of 0.3 mL of 1-(2-pyrimidyl)piperazine (1.83 mmol) and 0.5 mL of 
Et3N (3.66 mmol) was added. The reaction was heated under reflux at 105 °C for 16 h. 
Then the reaction mixture was cooled, water was added and the product was extracted 
with CH2Cl2. The organic phase was dried over anhydrous Na2SO4, filtrated and after 
that, the solvent was evaporated under reduce pressure to obtain a crude residue, which 
was purified by silica gel flash chromatography, using EtOAc/petroleum ether 1/1 as 
eluent, to obtain 23 (516 mg, 1.53 mmol) as a yellow solid. 
 
Yield: 50% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.29-8.31 (d, 2H, pyridine, J= 4.8 Hz); 7.85-7.89 (m, 2H, 
Ar); 7.71-7.76 (m, 2H, Ar); 6.47-6.49 (t, 1H, pyridine, J=  9.6 Hz); 3.87-3.90 (t, 2H, 
CH2, J= 13.2 Hz); 3.77-3.79 (m, 4H, piperazine); 2.69-2.72 (t, 2H, CH2, J= 12.8 Hz); 
2.59-2.62 (m, 4H, piperazine). 
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2-[4-(pyrimidin-2-yl)piperazin-1-yl] ethanamine (24) 
 
483 mg of 23 (1.43 mmol) were solubilized in 10 mL of EtOH under stirring. To this 
solution 0.3 mL of NH2NH2 monohydrate (4.30 mmol) was added and the mixture was 
heated under reflux at 105 °C for 5 hours. When the reaction mixture was cooled to 0 
°C, it was alkalized with 5% NaOH until pH=8. After the evaporation of the solvent 
under reduced pression, the product was extracted with CH2Cl2 and washed with H2O. 
The organic layer was dried over anhydrous Na2SO4 and evaporated to obtain 24 (277 
mg, 1.34 mmol) as a yellow solid. 
 
Yield: 93% 
 
1
H-NMR: (DMSO) δ (ppm) 8.37-8.38 (d, 2H, pyrimidine, J= 4.4 Hz); 6.63-6.65 (t, 1H, 
pyrimidine, J= 9.2 Hz); 3.73-3.75 (m, 4H, piperazine); 2.54-2.54 (t, 2H, CH2, J= 3.6 
Hz); 2.44- 2.49 (m, 4H, piperazine); 2.36-2.39 (t, 2H, CH2, J= 12.4 Hz). 
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N-[2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethyl] benzamide 
(9) 
 
277 mg of 24 (1.34 mmol) and 0.3 mL of Et3N (2.00 mmol) were dissolved in 3.4 mL 
of CH2Cl2. To this solution 0.2 mL of benzoyl chloride (1.34 mmol) were added 
dropwise at 0 °C. The mixture was heated to room temperature and left under stirring 
for 4 h. Then the reaction mixture was partitioned between water and CH2Cl2 and 
extracted with CH2Cl2. The organic phase was dried over anhydrous Na2SO4, filtered 
and the solvent evaporated to give a crude residue which was purified by silica gel flash 
chromatography (100 % EtOAc to EtOAc/MeOH 8:2), to obtain pure 9 (48.5 mg, 0.16 
mmol) as a yellow solid. 
 
Yield: 12% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.31-8.32 (d, 2H, pyrimidine, J= 4.8 Hz); 7.83-7.85 (m, 2H, 
Ar); 7.49-7.52 (m, 1H, Ar); 7.42-7.46 (m, 2H, Ar); 6.51-6.54 (t, 1H, pyrimidine, J= 9.6 
Hz); 3.92-3.94 (m, 4H, piperazine); 3.65-3.69 (t, 2H, CH2, J= 16 Hz); 2.75-2.78 (t, 2H, 
CH2, J= 10.8 Hz). 
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N-[2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethyl]-[1,1’-
biphenyl]-4-carboxamide (10) 
 
[1,1’- biphenyl]-4-carboxylic acid (130 mg, 0.60 mmol) was refluxed with SOCl2 (0.67 
mL, 9.24 mmol) at 85 °C for 3 h. After the excess of SOCl2 was evaporated under 
nitrogen atmosphere to afford [1,1’- biphenyl]-4-carbonyl chloride, which was directly 
used for the subsequent step. Then it was dissolved in anhydrous CH2Cl2 (0.6 mL), 
cooled to 0 °C and added of a solution of 24 (150 mg, 0.72 mmol) and Et3N (0.2 mL, 
1.44 mmol) in anhydrous CH2Cl2 (0.6 mL). The mixture was heated to room 
temperature and left under stirring for 4 h. Then the reaction mixture was diluted with 
CH2Cl2 and washed with water. The organic layer was dried over Na2SO4, filtered and 
the solvent evaporated under vacuum to obtain pure 10 (176 mg, 0.46 mmol) as a 
yellow solid. 
 
Yield: 64% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.30-8.31 (d, 2H, pyrimidine, J= 4.8 Hz); 7.86-7.88 (m, 2H, 
Ar); 7.66-7.64 (m, 2H, Ar); 7.58-7.61 (m, 2H, Ar); 7.43-7.47 (m, 2H, Ar); 7.35-7.39 (m, 
1H, Ar); 6.49-6.51 (t, 1H, pyrimidine, J= 9.6 Hz); 3.87-3.89 (m, 4H, Ar); 3.61-3.65 (t, 
2H, CH2, J= 16.8 Hz); 2.68-2.71 (t, 2H, CH2, J= 11.6 Hz); 2.60-2.62 (m, 4H, 
piperazine). 
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(+)-2-(4-isobutylphenyl)-N-[2-(4-(pyrimidin-2-
yl)piperazin-1-yl) ethyl] propanamide (11) 
 
(134.8 mg, 0.60 mmol) of (+)-2-(4-isobutylphenyl)propanoic acid was refluxed with 
SOCl2 (0.142 mL, 1.96 mmol) at 85 °C for 3 h. After the excess of SOCl2 was 
evaporated under nitrogen atmosphere to afford (+)-2-(4-isobutylphenyl)propanoyl 
chloride, which was directly used for the subsequent step. Then it was dissolved in 
anhydrous CH2Cl2 (0.6 mL), cooled to 0 °C, and added of a solution of 150 mg of 24 
(0.72 mmol), 0.2 mL of Et3N (1.44 mmol) in 0.6 mL of CH2Cl2. The reaction mixture 
was heated to room temperature and left under stirring for 4 h. Then the reaction was 
diluted with water and extracted several times with CH2Cl2; the organic phase was dried 
over anhydrous Na2SO4, filtered and evaporated under vacuum to give a crude, which 
was purified by silica gel flash chromatography, (100 % EtOAc to MeOH) to obtain 
pure 11 (52 mg, 0.13 mmol) as a yellow solid. 
 
Yield: 19% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.28-8.30 (d, 2H, pyrimidine, J= 4.4 Hz); 7.19-7.21 (m, 2H, 
Ar); 7.09-7.12 (m, 2H, Ar); 6.47-6.49 (t, 1H, pyrimidine, J= 9.2 Hz); 3.78 (s, 1H, NH); 
3.63-3.66 (m, 4H, piperazine); 3.53-3.58 (q, 1H, CH, J= 7.6 Hz); 3.28-3.32 (m, 2H, 
CH2); 2.36-2.44 (m, 8H, 4H piperazine, 2H CH2, 2H CH2); 1.75-1.83 (m, 1H, CH); 
1.51-1.53 (d, 3H, CH3, J= 7.2 Hz); 0.84-0.85 (d, 6H, 2CH3, J= 6.8 Hz). 
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2-[3-(4-(pyrimidin-2-yl) piperazin-1-yl) propyl] 
isoindoline-1,3-dione (26) 
 
1.34 g of N-(3-bromopropyl)phtalimide (5.00 mmol) were solubilized in 25 mL of ACN 
and 1.4 mL of Et3N (10 mmol) and 0.7 mL of 1-(2-pyrimidyl)piperazine (5.00 mmol) 
were added. The solution was heated under reflux for 16 h. After cooling, the mixture 
was diluted with water and extracted with CH2Cl2. The organic layer was dried over 
anhydrous Na2SO4, filtered and the solvent evaporated to drieness to give 26 (1.5 g, 
4.55 mmol) as a yellow solid pure enough for further reactions. 
 
Yield: 46% 
 
1
H-NMR: (CDCl3) δ (ppm)  8.23-8.24 (d, 2H, pyrimidine, J=4.7 Hz); 7.78-7.83 (m, 2H, 
Ar); 7.65-7.69 (m, 2H, Ar); 6.42-6.43 (t, 1H, pyrimidine, J=4.7 Hz); 3.75-3.78 (t, 2H, 
CH2, J=13.7 Hz); 3.64-3.66 (m, 4H, piperazine); 2.41-2.46 (m, 4H, piperazine); 1.96-
1.98 (m, 2H, CH2); 1.86-1.93 (m, 2H, CH2). 
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3-[4-(pyrimidin-2-yl)piperazin-1-yl)propan-1-amine (27) 
 
Compound 26 (1.0 g, 2.95 mmol) was dissolved in EtOH (20.6 mL) under stirring and 
after NH2NH2 monohydrate (0.7 mL, 9.7 mmol) was added. The mixture was heated 
under reflux at 105 °C for 5 h. Then the solvent was evaporated under vaccum and the 
residue was diluted with water and treated with CH2Cl2. The organic layer was dried 
over anhydrous Na2SO4, filtered and evaporated to drieness to give 27 (493 mg, 2.23 
mmol) as a yellow oil which does not need further purification. 
 
Yield: 76% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.27-8.29 (d, 2H, pyrimidine, J= 6.2 Hz); 6.44-6.47 (t, 1H, 
pyrimidine, J= 9.5 Hz); 4.95 (s, 2H, NH2); 3.77-3.82 (m, 4H, piperazine); 2.74-2.77 (m, 
2H, CH2); 2.40-2.49 (m, 6H, 4H piperazine, 2H CH2); 1.63-1.84 (m, 2H, CH2). 
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N-[3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl] benzamide 
(12) 
 
150 mg of 27 (0.68 mmol) and 0.1 mL of Et3N (1.02 mmol) were dissolved in 1.7 mL 
of CH2Cl2. To this solution, 0.07 mL of benzoyl chloride (0.68 mmol) was added 
dropwise at 0 °C. The mixture was heated to room temperature and left under stirring 
for 4 h. Then the reaction mixture was partitioned between water and CH2Cl2, and was 
extracted with CH2Cl2. The organic phase was dried over Na2SO4, filtered and the 
solvent evaporated to give a crude residue which was purified by silica gel flash 
chromatography, with EtOAc/petroleum ether 1:1 as eluent, to obtain pure 12 (25 mg, 
0.08 mmol) as a white solid. 
 
Yield: 12% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.30-8.31 (d, 2H, pyrimidine, J= 4.8 Hz); 7.99 (bs, 1H, 
NH); 7.79-7.82 (m, 2H, Ar); 7.38-7.48 (m, 3H, Ar); 6.49-6.51 (t, 1H, pyrimidine, J= 9.2 
Hz); 3.82-3.84 (m, 4H, piperazine); 3.58-3.62 (m, 2H, CH2); 2.55-2.62 (m, 6H, 4H 
piperazine, 2H CH2); 1.77-1.88 (m, 2H, CH2).  
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N-[3-(4-(pyrimidin-2-yl) piperazin-1-yl)propyl]-[1,1’-
biphenyl]-4-carboxamide (13) 
 
[1,1’- biphenyl]-4-carboxylic acid (232 mg, 1.17 mmol) was refluxed with SOCl2 (1.19 
mL, 16.39 mmol) at 85 °C for 3 h. After the excess of SOCl2 was evaporated under 
nitrogen atmosphere to afford [1,1’- biphenyl]-4-carbonyl chloride, which was directly 
used for the subsequent step. Then it was dissolved in anhydrous CH2Cl2 (1.1 mL), 
cooled to 0 °C and added of a solution of 18 (283 mg, 1.28 mmol) and Et3N (0.4 mL, 
2.56 mmol) in anhydrous CH2Cl2 (1.1 mL). The mixture was heated to room 
temperature and left under stirring for 4 h. Then the reaction mixture was diluted with 
water and exctracted with CH2Cl2. The organic layer was dried over anhydrous Na2SO4, 
filtered and the solvent evaporated under vacuum. The crude obtained was purified by 
silica gel gradient flash chromatography, using a gradient (100 % EtOAc to 
EtOAc/MeOH 9:1), to obtain pure 13 (104 mg, 0.26 mmol) as a yellow solid.  
Yield: 20% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.30-8.32 (d, 2H, pyridine, J= 4.8 Hz); 7.92-7.94 (m, 2H, 
Ar); 7.57-7.65 (m, 2H, Ar); 7.41-7.46 (m, 2H, Ar); 7.26-7.38 (m, 1H, Ar); 6.51-6.54 (t, 
1H, pyrimidine, J= 9.6 Hz); 3.94-3.98 (m, 4H, piperazine); 3.62-3.67 (m, 2H, CH2); 
2.54-2.77 (m, 4H, piperazine); 1.94-1.95 (m, 2H, CH2); 1.22-1.28 (m, 2H, CH2).  
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(+)-2-(4-isobutylphenyl)-N-[3-(4-(pyrimidin-2-yl) 
piperazin-1-yl) propyl] propanamide (14) 
 
(500 mg, 2.42 mmol) of (+)-2-(4-isobutylphenyl)propanoic acid was refluxed with 
SOCl2 (0.527 mL, 7.27 mmol) at 85 °C for 3 h. After the excess of SOCl2 was 
evaporated under nitrogen atmosphere to afford (+)-2-(4-isobutylphenyl)propanoyl 
chloride, which was directly used for the subsequent step. Then it was dissolved in 
anhydrous CH2Cl2 (2.30 mL), cooled to 0 °C, and added of a solution of 600 mg of 18 
(2.71 mmol) and 0.75 mL of Et3N (5.42 mmol) in 3.20 mL of CH2Cl2. The reaction 
mixture was heated to room temperature and left under stirring for 4 h. Then the 
reaction was quenched with water and extracted several times witn CH2Cl2. The organic 
phase was dried over anhydrous Na2SO4, filtered and evaporated under vacuum to give 
a crude, which was purified by silica gel flash chromatography using a mixture of 
EtOAc/ petroleum ether 1/1 as eluent, to give the pure compound 14 as a light yellow 
solid (251 mg, 0.62 mmol). 
 
Yield: 23% 
 
1
H-NMR: (CDCl3) δ (ppm) 8.303-8.315 (d, 2H, pyrimidine, J= 4.8 Hz); 7.187-7.207 
(m, 2H, Ar); 7.008-7.077 (m, 2H, Ar); 6.510-6.534 (t, 1H, pyrimidine, J= 9.6 Hz); 3.78 
(s, 1H, NH); 3.791-3.809 (m, 4H, piperazine); 3.466-3.520 (q, 1H, CH, J= 7.6 Hz); 
3.238-3.280 (m, 2H, CH2); 2.515-2.593 (m, 4H, piperazine); 2.427-2.458 (m, 2H, CH2); 
2.040-2.167 (m, 2H, CH2); 1.782-1.849 (m, 2H, CH2); 1.677-1.743 (m, 1H, CH); 1.459-
1.477 (d, 3H, CH3, J= 7.2 Hz); 0.854-0.882 (d, 6H, 2CH3, J= 6.8 Hz). 
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